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Abstract
Female mice of the S W RIHm (SWR) inbred stra in are susceptib le to the
spo ntaneo us initiati on of juvenile-on set granulosa cell (GC ) tumours of the ova ry a t the
onse t of puberty. T he mou se GC tum our s sha re hist olo g ical , endocrino log ical and
mali gn ant featur es w ith ju venile -t ype GC tumour s found in infant s and youn g girls , and
thus the SW Rstra in repr esent s a mod el sys tem for the idcntifi cat ion of susce ptibi lity
genes. Ge netic mappin g stud ies betw een the SW R stra in and tumour-resis tant stra ins
have co ns istently asso ciated the Gra nulosa cell tumour susce ptibility I (Get /) locu s on
dis ta l mou se chromos ome (Chr) 4 with the GC tumour phenotype . Mapping the trait fix
dch ydrocpiandrostcronc (DII EA) induced GC tumour appe aranc e in s ix con gcni c mou se
sublincs succe ssfu lly resol ved the Gct l locu s to 1.51 Mb and a candidatclist o f 23 uniqu e
anno tate d protein cod ing genes , non- codin g RNA genes , and o the r proc essed tran script s
whic h may repr esent novel ge nes with biol ogical activ ity. A qu alit ati ve ass ess me nt o f
pr ior itized genes within the refined Get I interval did not ex clude any from the ovar ian
co mpa rtme nt and therefor e sha red ide ntity wi th Gct l . Tnf rsfl b was g iven top prior ity as
a ca ndida te gene g iven its described role in ovari an biolo gy, but no con clu siv e sequence
va riatio n or expr ession differences uniqu e to S W R were identified that ind ica ted Tnfrsf l b
is Gct l . Three othe r prot e in cod ing ge nes (Dhr s3, Tn/i's/S, and Vps I3d ) a rc pre sen t in the
Get I reg ion and ortho logous between mou se and hum an , and arc promi sin g ca nd idates
for Gct l .
Acknowledgments
First and foremost, I would like to thank my supervisor, Dr. Ann Dorward, for
giving me this opportunity, having patience during my graduate training, and teaching me
to think critically. I am also indebted to Dr. Dorward for helping to further my academic
career by allowing me to attend conferences and apply for funding and scholarships. Ilcr
tireless efforts and great attitude towards research have not gone unnoticed, and I look
forward to the next four years in the Dorward laboratory as I start my PhD program.
I would like to thank my supervisory committee, Dr. Scvtap Savas and Dr. Laura
Gillespie. Their valuable comments and criticisms were greatly appreciatcd. Thanks also
lot heM acPhee laboratory, for welcome feedback throughout my graduate program.
Thank you to the members of the Dorward lab, past and present. for technical
help: Heidi Wells, Chris Hough, Sarah IIalfyard, Daniello Jackson, Clare Lewis, Ed
Yaskowiak, and others. Thanks especially to Katie Macdonald, for being a great friend
as well as a lab mate.
I would like to acknowledge the funding agencies that have financially supported
me and this project: the Canadian Institutes of Ilcalth Research, Newfoundland and
Labrador's Department of Innovation, Trade and Rural Development, and Memorial
University of Newfoundland's School of Graduate Studies. Thanks also to the Faculty of
Medicine's Office of Research and Graduate Studies, the Canadian Cancer Society and
the Beatrice Ilunter Cancer Research Institute fort ravel funds.
iii
f inally, thank you 10 my friends, family, and loved ones. Your support and
encouragement has been immeasurable
iv
Ta ble ofContents
Abstract ii
Ac k now led gme nts iii
Ta ble ufContents v
List of Ta b les vii
List of Flgures viii
List ofAbbrevia tions x
List of Ap pe nd ices xiv
Introduction 1
1. 1 O varia n Physiolo gy .... . 1
1.2 O varian Ca nccr .. . 13
1.2. 1 Granulosa Cell Tumo urs ofthc O var y .. . . 15
I. J An imaIModels of Granu losa CcIl Tum ouri gcn csis ... .. 19
1.3.1 T he SW RIBm Mou se Model o fJuveni le GC T umo ur igcncs is 23
1.4.llypoth csis and Research Obj ectiv es ...
2. Ma ter ia ls and Me t ho ds 1
2. 1 Animal Husband ry ... .
2.2 Phcnoty pic Ma pping .
.... .... ... . .... ... .. .... .. ... . .. .. ..... . .. .... ..... ...... .. .... ... 4 1
~~~~~~~~~~~~~~~~~
2.2 . 1 Gc noty pingbyS implcScq ucncc Lcngt h Pol ymorphism s 4 6
2 .2.2 Gc noty pingby Sing lc Nuc leo tide Polym orphi sm s . 4 9
2.3 Se rum Analysis . 54
2.4 Ge ne Ex press ion An alyscs ... . 55
2.4 . 1 Qu alitati vc Gcnc Ex press ion Ana lys is .., . 6!
2.4 .2 Qu ant itati ve Ge ne Exprcss ionAna!ys is ... . 63
2.5 Ca nd ida tcGcnc Scqucnc ing ... . 6 7
3. Result s 69
3. l l'hcnolypic Mapping ofG ct l ... . .... ..... ..................... 69
3.1. 1 Development oft he Linc 4-3 Recombinant Subcongcnic Lines ... . 69
3. 1.2 Rcfining thc Gcnclic Bollndarics of Gct l ... . 7 \
3.2 The Refined Get I Interval 76
3.2.1. In sili co Data ...
3.2.2 Qualitative Gene Exprcssion Analysis ...
........ ...... ............ ....... ... 76
.. g l
3.2.3 Quantitative Gene Exprcssion Analysis g2
3.2.4 Tn/i·.I'/JhScq llcncing gS
4. Discu ssion 911
4.1 Gct l Rcsidcs Wilhina 1.51 Mb lnlcrval. 9 \
4.2 I'riorilizing GctI Candidalcs: Qualitative Expression Analysis 92
4.3 Thc Gct l lnlcrvali n Mollsca nd llllman.... ..... .......... ............. .... .... ........... . 93
4.4S lImmary 101
4.SFlI lUrc Dircctions... . .... .......... ............. \02
5. References 111...
vi
ListofT:lbles
Table 1.1 Genetically engineered mouse models of sex cord-stromal tumours 21
Table 1.2 Autosomal and X-linkcd loci associated with GC tumour
susceptibility in SWR mice 27
Table 1.3 Descriptions of inbred and congenic mouse strains 39
Table 2. 1 SSLP and SNP gcnotyping markers .47
Table 2.2 Qualitative expression analysis primers 62
Table 2.3 Tnfrsf l b sequencing primers... . 6R
Table 3.1 SSLP and SNP gcnotyping markers 72
Table 3.2 Annotated and novel SNPs identified within gene candidates 74
Table 3.3 Annotated andnovel SNPs identitiedwithinlh ethlgment
amplitied by D4kns / .....
Table 3.4 Summaryo ft hegenetic determinants within lhe 1.51 Mb
GCI/ interval...
Table 3.5 Relative gene expression in the mouse gonad RU
Table 3.6 Qualitativeexpression ofthe Gcl/transcriptsw ithinlhe
1.51 Mbinterval R3
Tab le 3.7 Serum DHEA Icvels in SWR and Line 4-T mice treated with
DI IEA or empty capsules...
Table 3.8 Nucleotide changes in SWR Tnfrsf l b cDNA versus 1:36 and Line 4-T .....RR
Table 4.1 Relative gene expression in human and mouse gonads 96
vii
Llsr ofFigu res
Figure 1.1 Ovarian anatomy and ccllularcomponcnts 2
Figure 1.2 Thc hypothalamic-pituitary-gonadal axis 3
Figure 1.3 Sex determination in the bipotcntial gonad ...
Figure 1.4 Ovarian folliculogcncsis 9
Figure 1.5 The two-cell, two-gonadotropin theory of follicle hormone
regulation and production 11
Figure 1.6 Bilateral GC tumours isolated from a genetically susceptible
female mouse ... . 24
Figure 1.7 Impael ofth e allelic eonstilution at Cel/ andtheendoerinc
environment onG C tumour susccptibilityi n female mice 30
Figure I.g The stero id biosynthctic pathway forthe conversion of substrate
cholesterol to androgens and estrogens... . 31
Figure 1.9 Isolating Cel l in a congcnic strain ... . 34
Figure l.10 Crcating subcongcnic strains to map Gct l :.. . 36
Figure 1.11 ChI'4 haplotypcs of SWR and Linc 4-T subcongcnic mouse
lincs at Cell ...
Figurc 2.1 Phenotypic mapping paradigm for GC tumour susceptibility
....3g
vers us resis tance . . .43
Figure 2.2 Sample collection paradigm for quantitative gene expression
in the ovary and serum analysis ... . .44
Figure 2.3 Quantitative Tnji'sjl hex press ion analysis paradigm 64
Figure 3.1 ChI'4 haplotypcs ofS WR, Line 4-3, and the SWR.SJL-X.CAST-4
reeombinants ubeongenie mouse lines at Gcl l 70
viii
Figure 3.2 Chr4 haplotypcs ofSW R. Line 4-3. and the SWR.SJL-X.CAS1'-4
rccornbinant subcongcnic mouse lines at the refined Gct l interval 77
Figure 3.3 Enscmbl scrccnshot of the 1.51 Mb GelI interval 7R
Figure 3.4 Fold change in Tnfrsfl b mRNA relative to Acth R6
Figure 3.5 Alignment of the SWR. Line 4-1' and 136 TnIrsfl b amino acid
sequences R7
Figure 4.1 Enscmbl screcnshot of the mouse GelI interval and the orthologous
human region on Chr Ip36.22 94
ix
List of Abb revia tions
°C degrees Celsius
Type I error
I) Type II error
fig microgra m
IlL microliter
11M micromolar
Act b mouseb eta-aetin gene
AMII anti-Mullerian hormone
A11/111'2 mouse AMH receptor type 2 gene
AI' mouse androgen receptor gene
136 C57BLl6
BCL 13eell lymphoma/ leukemia
BMP2 bone morphogenetic protein 2
bp base pair
BRCA I human breast cancer I, early onset gene
BRCA2 human breast cancer 2, early onset gene
C CAST allele
CAST Castancus
CD99 Cluster of Differentiation 99
cDNA complementary DNA
ChI' chromosome
c-IAP I cellular inhibitorofapoptosis l
c-IAP2 cellular inhibitor of apoptosis 2
em centimeter
CO2 carbon dioxide
CT threshold cycle
Ctnnb l mousc catenin (cadherin assoc iate protein), bcta I gene
Cys cysteine
d day
dbSNP Single Nucleotide Polymorph ism Databasc
DIIEA dehydroepiandrostcrone
Dllrs3 mouse dehydrogenase/reductase (SDR family) member 3 gcne
D/l RS3 human dehydrogenase/reductase gene (SDR family) member 3 gene
DIIT dihydrotestosterone
DNA deoxyribonucleic acid
DNase deoxyribonuclease
dNTP dcoxynuclcotidc triphosphate
E embryonic day
E primer efficie ncy
E2
EDTA
ELISA
P
FancdI
FIGO
FOXU
FOXL2
FSII
FI'1I1'
g
GC
Ge l
GDF9
gDNA
GnRl1
II
h
hCG
uci
IIPC,
lnha
Iso-lI i-pll
J
JNK
kg
KIT
KITL
KUli S
L
L11
Lhb
Linc 4-3
Linc 4-T
M
MAPK
Mb
MellI
mg
MGD
min
mL
mm
mM
17r)-cstradiol
cthylcncdiaminctctraaccticaci d
cnzymc-linkcdi mmunosorbcnta ssay
filial generation
mouse fanconi anemia, complcmcntation group D2 gene
International PcdcralionofGynccologyand Obslclrics
human forkhcad box L2 gene
human forkhcad box L2 protein
follicle-stimulating hormone
mouse follicle-stimulating hormone receptor gene
gram
granulosac cll
granulosace ll tumours usccptibilily
growth d iffe rent iat ion factorv
gcnomie DNA
gonadotropin-releasing hormone
height
hour
human chorionic gonadotropin
hydrochloric acid
hypothalumic-pituitary-gonadul
mouse inhibin-alpha gene
isotonic high pll
SJLallcic
JunN -lerminal kinase
kilogram
kit ligand rece ptor
kit ligand
human v-Ki-ras2Krislen rat sarcoma viral oneogeneh omolog gene
length
luteinizing hormone
mouse luteinizing hormone beta gcne
SWR,SJL-X,CAST-4-3
SWR,SJL-X,CAST-4-T
molar
mitogen-act ivated protein kinase
mcgabase
mouse multiple endocrine neoplasia I genc
milligrams
Mouse Genome Database
minute
milliliter
millimeter
millimolar
xi
MMLV-RT
mo
mRNA
Mt hfr
n
N
NC131
NF-K13
ng
nm
No box
Nbhp
OM IM
P
PCR
PGC
Phc
pmol
PTEN
qPCR
RA
RI
RNA
RNasc
rRNA
RSPOI
RT
SCST
SOR
SCI'
SJL
Sm ad l
Smad5
SNP
So hlli l
So hlh2
SOX9
SUY
SSLP
STK II
SW
SWR
SWXJ
Moloney murine leukemia virus reverse transcriptasc
month
messenger RNA
mouse 5, IO-methylenetetrahyrdofolate gene
sample size
backcross generation
National Center for Biotechnology Inform ation
nuclear factor kappa 13
nanograms
nanometer
mousenewborn ovary homeobox gene
mouse natriuretic peptide type B gene
Online Mendelian Inheritance in Man
p-valuc
polymerase chain reaction
primordial germ cell
phenylalanine
picom o lc
human phosphatase and tensin homolog gene
quantitative real time polymerase chain reaction
rctinoic acid
recombinant inbred
ribonucleic acid
ribonuclease
ribosomal RNA
R-spondin I
room temperature
second
sex cord-stromal tumour
short-chain dehydrogenase/reductase
serine
SJLll3m
mouse MAO homolog I gene
mouse MAO homolog 5 gene
single nucleotide polymorphism
mouse spermatogenesis and oogenesis helix-loop-helix I gene
mouse spermatogenesis and oogenesis helix-loop-helix 2 gene
(sex-determining region Y)-box gene 9 gene
sex-determining region on the Y chromosome gene
simple sequence length polymorphism
human serine/threonine kinase II gene
SWR allele
SWR/l3m
(SWR x SJL)
xii
T
Taq
T HE
TE
TG F I~
TNFa
TII/i-s/ia
Tnfrsfl b
Tnfrsfl b
TII/i -s/<,~
TP53
TRAF2
Trp
Trp53
UI3A
UTR
V
Vpsl3d
VPSI3D
W
w /v
wk
WNT4
testosterone
Thcrrnus aquaticus
tris borate ethylenediaminetetraaeetie acid
tris cthylcncdiaminctctraacctic acid
transforming growth factor beta
tumour necrosis factor alpha
mouse tumour necrosis factor receptor superfamily. member Ia gene
mouse tumour necrosis factor receptor superfamily. member Ib gene
mouse tumour necrosis factor receptor superfamily, member Ib protein
mouse tumour necrosis factor receptor superfamily, member 8 gene
human tumour protein 53 gene
TNF receptorassociatedfactor2
tryptophan
mouse transformation related protein 53 gene
ubiquitin-associatcd dornain
untranslated region
volt
mouse vacuolar protein sorting 13 D (yeast) gene
human vacuolar protein sorting 13 D (yeast) gene
width
mass concentration
week
wingless-type MMTV integration site family, member 4
xiii
Appendix A Contributions ...
List of Appe nd ices
. 115
Appendix B Copyright permission 116
Appendix C l larvard PrimcrBank 1Ds for primer sequences used in the
qua litati ve ge ne exp ression analysis ... . 119
Appendix D Alignment oft he SWR. Line 4-T, and 136 Tnfrsfl b cDNA
nucleotide sequences 120
xiv
I. Introduction
1.1 Ovarian Physiology
Overview
The mamma lian ovary is a highly specia lized reproductive organ withtwo
primary roles, the first of which is gametogenesis, or the production and release of
developmentally competent haploid oocytes. Secondly, the ovary is an endocrine orga n.
and steroid hormone production by ovarian cells is critical for germ cell fertilization and
embryo implantation . as well as other long term physiologic functions necessary for
developme nt of the adult organism. The mature ovary is enclosed within the ovarian
bursa. and consists of an inner zone. the medulla, and an outerzone, the cortex (Figure
1.1). The medulla is highly vascularized and contains lymphatic vesse ls. nerves. and
connective tissue. The cortex is covered by a layero fsp ecialized surface epithelium, and
immedia tely beneath this layer is the tunica albugi nea. a dense strip of interst itial cells .
Ovarian development is a complex process that begins with the specificatio n and
differentia tion of primitive germ cells in the early embryo, followed by the organization
of germ cells and somatic cells into ovaria n follicles. The foll icles. which reside in the
cortical region. arc the functional unit of the ovary that support the growing oocyte and
are the source of estrogens and androgens. The hypothalamic-pituitary-gonadal (I IPG)
axis plays a critical role in normal follicle development (Figure 1.2). The hypothalamus
secretes gonadotropin-releasing hormone (Gn RH), which stimulates the gonado trope
Gf~lrlU 'O!>tl cells l OfM oeuoc a
Prlrn"'Y00C)1\~ se-cond8iY 'OIIiCle Artttum
Secoooat v oocvte
Zon.lpelJ ..lCl<Ja
Figurc 1.1 Ovariuu unatumy and ce llu lar component s
T he ova rian corte x is cove red by a layer of surfa ce epit he lium , immediatel y above the
den se tunica a lbugi nea . Follicle s com posed of a sing le ooc yte surro unded by the somati c
granulosa and thec a l ce lls reside amo ngst the inte rs titial ce lls in the cortica l regio n. The
innermedu llaish igh ly vaseul ari zed andeontain sl ymp hatic vessel s, ner ves, and
connec tive tissue (Co py right © 20 10 by The McGraw - ll ill Co mpanies, Inc, used with
perm ission ).
G17~-Est ra d io l __-
Figure 1.2 T he hyp othal amic -pitui tary-gon ad al axis
The hypothalamus secretes GnRl 1.which stimulates the gonadotropc cells of the anterior
pituitary to release follicle-stimulating hormone (FSII) and luteinizing hormone (L1I).
Positivc andncgativefccdback by steroids from the ovarian follicles stimulates and
rcpresscs thcs ecrction of FS11and L11depending on thc follicle' s phase of growth.
ccllsoft hcanterior pituitary to rclcasc FSII and L11. These gonadotropin hormone s arc
cyclically regulated through both positive and negative feedback from the ovarian
folliclcs tollowing the pubertal transition. stimulating folliculargrowth and ultimate ly
rcsultin ginthepreparation ofm ature oocytes ti)J"ovulation.
Ovarian Developm ent
The gonads develop as bilateral thickenings of coe lomic epithelium at the genital
ridge. a region on the ventromedia l surface of the embryonic kidney. or mesonephros.
during wee k (wk) four of gestation in humans or embryonic day (E) 9.5 in the mouse
(van Wagenenand Simpson 1965. Kaufman 1991). The primitive gonad is sex ually
undiffe rentiated and bipotential; it may differentiate into the testes or ova ries. depend ing
on the presence or absence of the y chromosome (Chr),and specifically the Sex-
determin ing region oil /he Y chromos ome (SRY) gene (Figure 1.3; Sinclair et al, 1990,
Koopm an e/ al . 199 1). The indiffer ent gonad initially eontains only somatic ce lls derived
from the coe lomic epithelium and mesonephros. Primord ial germ cells (PGCs) . the
precursors of mature oocytcs, are initially identical in XX and XY gonads. Prior to
gonad formation. PGCs in the mouse different iate from a clustered cohort of
approx imately 45 proximal epiblast progenitor cells, adjacent to the extraemb ryonic
ectoderm at the base of the allantois (Gardner and Rossant 1979. Lawson and Ilage
1994). Following the breakdown of the I'GC cluster, individual PGCs migrate to the
genital ridge durin g the fi fth wk of gestation in humans and from E9.5 to E11.5 in the
Bipote ntia l Gonad
o
~~ / y
/ / SRY
WNT4 ./
RSPOl - S-catenin I SOX9
© @• •
Ov ary Testis
1 1
FOXL2 SOX9
Fig ure 1.3 Sex detcrmin ati on in thc bipo tcntia l go nad
W NT4 (W ing less- type MM T V integrati on si te fam ily, memb er 4) and RS PO I (R-
spond in I) stabi lize II-eaten in in the embryon ic XX go nad, prevent ing the 51?}'-indu ccd
express ion of 50)(9 and subsequent testi s for mat ion . Fo llowing ova rian de vel opm en t.
FOXL 2 (Fork hcad box L2) ac tive ly mainta ins ov aria n so ma tic cell d ifferen tiation .
Ada pted fro m Uhlcnhautel a /. (2009 ).
mouse (Everett 1943, Mintz and Russell 1957, Kurilo 198 I). Dorsal PGC migration fro m
thcallantois through the hindgut is directed by thc chcmoattractant signaling action of
KIT ligand (KITL) and its receptor KIT (Farini el 01.2 007) . KITL/KIT signaling is also
required for PGC survival during migration (reviewed by Saga 2008). Throughout
migration and colonization oft he gonad, the PGCs undergo mitotic proliferat ion which
expands the population to around 26,000 cells in thc mousc( Bowlcs and Koopman
2007). At this point in embryogenesis, the gonad is still indiffcrcnt and PGC
differentiation, migration, and proliferation arc idcntical between XY and XX embryos.
However, around thc timc of gonad colonization, XY gonads express SI?l', which acts
through its target gene, (Sex-de termining region Yl -box gene 9 (SOX9) to triggcr the
differentiation oft hc gonad towards a testis fatc( l lackcrelal. 1995, Jeske et 01. 1995,
Sckido ct 01.2004). PGCs in XX gonads diffe rentiate into oogonia: once thought to be a
passivc, detflldl pathway duc to thca bscnccofSI?l', female gonad differentiation is now
known to be an active process regulated by WNT4 (Wingless-type MMTV integration
site family, member 4) and RSPO I (R-spondin I). As shown in Figure 1.3, WNT4 and
RSPO I stabil ize [l-catcnin. inhibiting SOX9 expression in the female gonad (Maatouk ct
01.2008). The transcription factor Forkhcad box L2 (FOXL2) is required to actively
suppress thc diffcrcntiution of ovarian somaticcc iis to the malc fatc post-gonad
diffe rentiation (Uhlcnhaut ct 01.2009) . Whcn XX gonad colonization is complete,
further mitotic prolife ration increases the germ cell pool, and by 20 wk gestation in
humans approximately seven million oogoniaarc present (Bake r 1963). Mitotic PGC
proliferation is characterized by incomplete cytokinesis, which results in clusters of
daughter cells connected by intracellular bridges, termed germ cell cysts (Pcpling and
Spradling 2( 0 1). The end of germ cell production, at wk 24 in humans or E13,5 in the
mouse, is marked by the initiation of meiosis. a process initiated by retinoie acid (RA). a
form of vitamin A (Bowles et al . 2006, Koubova et al. 2006). The oogonia proceed
through the leptotene. zygotene and pachytene stages of prophase I. but arrest at the
diplotene stage. Now callcd primary oocytcs, the diploid germ cells remain in a perpetual
quiescent state until ju st before ovulation when they complete thc tirst meiotic divis ion,
Inth e secondtrimcstcr ofhumandcvclopmcntand immcdiatcl y atierbirth in the mouse.
germ cell cysts begin to breakdown . Tbc oocytcs arc subjcct to cxtcnsivc apoptosis
during cyst breakdown (Ruby et al . 1969, Pcpling and Spradlin g 200 I) . This process,
tcrmcd oocytc uurition. is thought to be controlled by the I3ccll Iymphoma/lcukcmia
(8 el) and caspasc protein families (reviewed by Tilly 20( 4). The survivin g oocytcs
constitutca tinitcand non-rcncwablcovarian rcscrvc. although it has reccntlyb een
postulated thatde llo \"() oocytcs arc able to differentiate from stem cells (Johnson et al.
2( 04).
Folliculogenesis
Folliculard evelopment is a tightly regulated process that relics on bi-directional
communi cation between thcoocyte and its surroundin g somatic ccllst ocoordinate
follicle growth. recruitment and selection in concert with follicle death (Eppig et al .
20(2) . Followin g breakdown of the germ cell cysts. thc rcmaining oocytcs become
organized into primordial follicles consisting of an oocyte surrounded by a single layer of
somat ic-derived,s quamous pre-granulosacclls( GCs; Figure 1.4). Abascmcn t
membrane separates the pre-GC laycrfromthc surroundin g stromalcells. cxeluding
vascu lar nctworks from thc inncrfolliclc (l3akcr 1963, Hirshfield 1991). Thc proccssof
follicular atresia, or death of thc follicles by apoptosis, begins aftcr the formation of
primordial follicles and continues throughout lifc. Oocytc attrition and follic ularatresia
result in substantial germ cell loss. such that the human ovary contains approximately one
million oocytcs within resting primordial foll icles at birth (l3akcr 19(3 ). The pool of
resting primordial follicles is depleted by follicle degeneration and the continuous
initiation of folli cle growth and ovulation. Thccxact molecularmechanisms that prompt
initial recruitment into thc growing population arc still undcr speculation. although a
numbcrof gcncs havc bccn implicated, Follicles in mice null fort hc Nell'!Jomm'wy
hO/l/eo!Jox( Noho x) gene cannot progress past thc primordial stagc (Rajkovic et al, 2004 ).
Micc with deletions of either the Sp erm atogen es is and oogenes is helix -loop -helix I
(Sohlhl ; gene or Sohlh? show a similar phenotype (Pangas ct al. 2006. Choi et al. 200X.
Ilao e/ al . 2008). Furthcrmorc. down-rcgulation ofK ITL duringcarly mousc
folliculogcnes is results in a dccrcascd pool of growing follicles compared to controls. as
wclla s arrcstcd growtha tt hc primordial stagc( Kuroda e/al. 19XX.lluang e/ a l. 1993.
Bedell et al. 1995). Primordial foll icles that cntcrt hc growing pool progress to thc
primary stage. which is marked by growth ofthc oocyte and its surrounding (i C layer, as
well as the FOXL2-dcpcndcnt transition ofGCs from a squamous to cuboidal
morphology (Schmidt et al . 2004. Uda et al. 2004). Cellular communication between
Figure 1.4 Ova r ia n fo llic uluge nesi s
Primord ial fo llic les that arc recru ited forgrowth from the quiescent pr imord ial poo l
progress to the primar y stage . Mult iple GC layer s and the theca laycr a re ch a ractcr istics
of seco nda ry fo ll ic les . Fo llow ing antrum format ion, se lec t fo llic les a rc recru ited for
Iurthc r growth. ulthough only one o ra subse t of these a rc eve ntua l!y ov ula tcd in hum ans
o r mo use , resp ectively (Co py rig ht © 20 I0 by The McGr aw-l lill Co mpa nies, Inc, used
with pe rm issio n) .
adjace nt GCs is achieved via gap junctions composed of homologous conncxin
complexes organized to form a conncxon structure with a centra l channel (Juneja el a/ .
1999). Follicles committed to the growt h phase also acquire a zona pcllucida between the
oocyte and GC layer. GCs extend cytoplasmic projections through the zona pcllucida to
contact the oocyte through heterologous connexo ns (Simon ct at. 1997). These gap
junc tion networks provide bi-directional comm unication between the oocyte and GCsand
arc essential for growth of the follicle and germ cell maturation. The oocyte-specific
Growth differe ntiation factor 9 (GDF9) is necessary forth e progression ofthe follicle
from the primary 10 secondary stage due to its promotion ofGC proliferation (Dong et at.
1996. Elvin et at. 1999). Secondary. or pre-antral. foll icles arc characterized by a double
layer ofG Cs around the oocyte, and an outer thecal cell layerthat diffcrcntiatcs from
surrounding stroma l cells . The theca is vascularized and provides a connection with the
body' s circulatory system (lli rshfie id 1991). Follicles progress to the antral stage when
the aggregation of small fluid-fi lled cavities forms the antrum, accompanied by the
different iation of the theca into two distinct layers: theca interna andthecacxtcrna.
The stages offolliculogcncs is prior to and including secondary f'olliclc formation
arc independent of the pituitary gonadotropins FSII and ULandt hc transit ion from prc-
antral to antral at the pubertal onset marks the start offollicularregulation by the IIPG
axis. The recruitment ofa small cohort of antral follicles for furthergrowthtermed
cyclic recruitment , occurs aftert he start of puberty. Cyclic follicle recruitment is initialed
by FSII; antral follicles that arc not recruited facc death by atresia , Expression of the
enzymes necessary forst eroid hormone production by follicular cells is controlled by
FSII and L11(Figure 1.5). GCs ina ntral follicles arc capable of producing 171)-estradiol
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Figure 1.5 Th e two- cell , two -go na dor ro p ln theory of fo llicle hormon e regnlation and
pro duction
L1l stilllu lat ionof thcca lcclls rcsultsint hccxprcssionof thcstcroidogc niccnzylllcs
necessary for androgen synt hes is fro m cho lestero l precursors, as well as the transport of
cho lestero l into thci nncr illitoc hond ria l lllcillbra nc . F5 11stimulatcs Gt.s und up -rcgulntcs
the enzy mes necessary fo r aro matization ofandro ge ns to es troge ns. and is lateressential
for thc cxprcssion ofL l l rcccp tors on thc Gtt surfacc .
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(E2) using androgenic substrates produced by the thecal cells in response to gonadotropin
stimulation. Low levels of E2secreted by GCs exert negative feedback on GnRl1
secretion from the hypothalamus, as well as FSII and l. ll sccrction from the pituitary,
preventing the FSl l-induccd development of new antral follicles within the same cycle.
Except in the case of dizygotic twins, a single follicle from the antral cohort is selected
for ovulation and becomes the dominant follicle in humans, whereas in mice, selection for
and ovula tion ofm ulriplc oocytcs occurs every cycle . The exact factors regulating
specific follicl e selection and dominance arc undefined. but may be due to a threshold of
FSII sensitivity (Fauser and van Housden 1997). Shortly before ovulation, increasing E2
levels peak and result in the positive regulation ofG nRH. High E21evels result in
dramatically increased lcvcls ofL l l. known as the L11surge. whereas FSII secretion is
negatively regulated by the GC-seerete d peptide hormone inhibin . During this time,
meiosis resumes within the dominant follicle germ cell. and the diploid primary oocyte
becomes a haploid secondary oocyte. TheUls urge resultsi nacascadeofeve nts leading
to the rupture of the ovarian surface epithelium and extrusion 0 fthc oocytc and its
surrounding GC layer. Following ovulation, the fo llicular remnants collapse and become
luteinized through terminal differentiation. forming the corpus lutcum, a transient and
highly vascularized progesterone-secreting tissue. The processes otfolliculogcncsis in
both species work conti nuously to recruit waves of follicle cohorts to the growing pool.
so that following ovu lation new folli cles have reached the antral stage and can become
destined for ovulatory dominance through cyclic recruitment. This repetitive process of
initial recruitment,fll lliciegrowth,andcycl ic recruitment, complemented by oocyte
attri tion and follicular atresia, create a balanced dynamic of lifc and dcath in thc ovary
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that eventually results in the complete depletion of the ovarian reserve at the close of
reproductive life .
1.2 Ovarian Cancer
Ovariancanceris the second mostcommongyneeological malignancy, and ranks
as the fifih deadliest cancer among Canadian women (Canadian Cancer Society 20 11).
Approxi mately I in 69 women will be diagnosed with and I in 92 women will succumb
to the disease annually (Canadian Cancer Society 20 1I). Ovarian cancer symptoms arc
generally non-specific or 'Ibsen I and reliable biomarkers arc 1'1ekingtwo factors which
contribute to the diagnosis of I'llcs tage tumours that show resistance to traditional
chemotherapeutic methods and often recur. The overall fivc- yearsurvival rate fors uch
late stage cases is approximalely3 0'Yo, though this figure increases to 80'Yt, fort hose
diagnosed early (Jcmal et al . 2008). The majority of women arc diagnosed during the
fifihand sixth decades of life, although ovarian cancer occurs in all age groups (Koonings
el a l . 1989 ).
Traditionally. human tumours of the ovary have typically bccn thought to arise
from one of the three ovarian cell components, and as such arc dividcd into three major
classes. Tumours arising from the surface epithelium surrounding the ovary. termed
epithelial ovarian tumours , accoun t for 90% of ovarian cancers (Crum 1999).
Approximate ly 7% of ovarian cancer s arc sex cord-stroma l tumours (SCSTs) derived
from cells specialized in steroid hormone production , including the granulosa and theca
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cells surrounding ovarian follicles (Colombo et al. 2007). Finally. germ cell tumours
derived from thc oocytcs rcprescnt 1-2'il. ofmalignant ovarian neoplasms (Pectasidcs el
al.2 008). The remaining percentage ofovarian tumours arc metastases from distant sites.
All three classes of ovarian cancer are further divided into distinct subtypes based mainly
on histology. Recent advances in the management of ovarian canccr havc focused on
recognizing and treating individual subtypes as separate diseases.
Thcsingle most common subtype of ovarian canccr in Canadian women is high-
gradescrouscarcinoma.asubtypeof thcc pithclialova rian tumour class( Klibcl elal.
20 10). Thcctiologyof malignantovariant umoursi s mcchanistically undctincd. and due
tot hc high incidcnccofepithclial ovarianca nccr.the majorityof rcscarch has been
focused on this tumour class. The ll1ostpopular thcoryofova riancanccro rigin is thatof
"incessant ovulation" (Fathalla 1971). which posits that ovulation disrupts the ovarian
surlilcee pitheliull1,a nd itss ubscqucnt proliferative repairincreases the risk fiJr the
accull1ulationo f delcterious ll1utations. This hypothesisissupportcd by thc protectivc
roles of ovulation-blocking oral contraceptive use and pregnancy.und the increased risk
associate d with early menarche and late menopause (Casagrande 1'1al. 1979. Purdie 1'1 al.
20(3) . Recently. researchers have proposed that some epithelial ovarian cancers arc
caused by the incorporation of dislodged fallopian tube epithelial cells into the ovary
following ovulation. or are in actuality secondary cancers arising from malignant lcsions
in nearby tissues, particularly the fallopian tube (Kurman and Shih 2010). The
observation that sulpingo-oophorcctomy trcmoval of the tilII0 pian tubes and ovaries)
reduces ovarian cancer risk. particularly in women with an incrcased risk due to familial
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mu tat ion s in the Breast cancer I, early onse t (BRCA I) and BRCA2 tumour suppre ssor
ge nes. supports this hypothesis (Kautf c/ o.'. 2002), l lowever, neither o f these theories
ex pla in events lead ing to malignancy in the SCST or germ cell tumou r type s. which arisc
fi'om dis tinctcell types below the ovariansurfa ce, Furthermore, a numbe r of soma tic and
gc nn linc mut ation s in human tumou r suppresso r ge nes and oncoge nes have been
associated with an incr eased risk of epithe lial ovarian cancer initi at ion and progre ssion .
includ ing BRe A I and BRe/12. Tumour protein 53 (TP53), v-Kl-rasZ Kristen rat sarco ma
vira l oncoge ne homolog (K RAS), and Phosphata se and tensin homolog (PTEN; review ed
by Bast et 01, 2009 ) - however. mut ation s in these genes arc not ge nera lly associated with
ova riantumo urs dcrived from oth er ce ll types, Fina lly, the inc reased risk assoc iated with
ov ulatory event s over a wo ma n's lifet ime is not applicable to juv cni lc form s ofo varian
cance r. sugg es ting a strong predisposin g genetic component for ovar ian ca nce r
susce pt ibility in such cas es,
1.2.1 Gra nulosa Ce ll Tum our s of the Ovary
Approxi ma tely 70% ofSCSTs arc GC tumours (Co lombo et 01, 200 7). which
accordi ng to the World Il ealth O rgani zation C lass ifica tion of Gy neco log ic Tumo urs. arc
SCSTs comp osed of a 10-100'y.,GC compone nt (Tavassoli et 01,2 003 ). GC tumo urs arc
divided into two clinico patholog ic subtypes, adult andj uveni lc, based on histo logy and
age at tum our diagnosis. Unlike epithelial ova rian ca nce rs,GC tumours occur at ei the r
end of the reproduct ive spect rum. Adult GC tumours arc more comm on , and typica lly
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occur in per i-and post-menopausal wome n (Bjorkholrn and Silfvcrsward 19RI) . Ju ven ile
GC tumours mo st comm onl y aff ec t young girls from newb orn s throug h ado lescence;
Youn g et al. ( 19R4) fo und 44'X, occu rred in the fir st dec ad e, 34% in the second, IR% in
the third,andonly 3%atier age30.
The rar ity of j uve nile GC tum our s in the hum an popu lati on has prec lude d
invc sti gations into the ir et io logy. I\. small numbe r of cases have oc curred in pati ent s w ith
O ilier d isease and Maffucc i sy nd rome (O M 1M 166(00), di seases characterized by the
develop ment of mulliple en eh ond rom as or ench ond romas andhcman giom as, rcsp ective ly
(Young ct al. 19R4 ). Ge ner a lly con side red spo rad ic, these co ndi tions have no t been
asso cia lcd w ilh anygenetic dete rminantsconfe rringsusc eptibility. GC tumour s ca n
develop inhumantcm aleswithPeu lz-Jc ghcr s syndrome (OMI M 1752(0). a
harm ato mous disease caus ed by genn line muta tions in the tum ou rsuppressor
Serine/threonine kinase I I (STKI I) gene (for me rly LKBI; Dozoi s et al. 1970 , Il emm inki
et al. 199R). l lowcvcr. Kato et al. (20 04) found no assoc iation bet we en sporad ic GC
tumours and STKI I mu tation s in pati ents w itho ut Peut z-J egh ers sy nd rome. bu t did find
loss o f hete rozygosity ncar the STKI I locu s in 50 % of spora d ic GC tum our s exami ned .
Loss of the w ild-type STKII alle le may therefore be a con sequ en ce of tum our
pro gression in spo rad ic cases. Recent ly, Shah ct al. (2009) perf orm ed wh ol e-
tra nsc riptomesequencing of adult (, C tumo urs, and ide nti fied a recurr en t. so ma tic
cA02C >G mut ati on in the 1"OXL2 gene. the tran script ion facto r requ ired to ma inta in
fema le gonad iden tity and GC di ffer ent iat ion dur ing foll icul ogcnc s is , in 97 % of cases
exa m ined, A lthough the mech an ism o f this p.Cys l3 4T rpmutation in adult CiC tum our
lfi
initiation is still unknown, it was notably absent from ju venile GCtumours,indicatingthe
two subtypes have distinct genetic etiologies (Al-Agha et at. 2011). Cytogenetic
aberrations, including trisomy ChI' 12 and monosomy Chr 22, have been detected in some
human ju venile GC tumours, although these events likely represent a consequence of
tumour progression rather than a requirement for tumour initiation (Schofield and
Fletcher 1992, Shashi et at. 1994, Halperin et at. 1995, Lindgren e! at. 1996).
The largest series ofhuman juvcnilc Gt,' tumours examined to date was reported
by Young et at. ( 1984). The majority of ju venile CiC tumours present with acute
endocrine symptoms, with or without a palpable abdominal mass. Abdominal pain and
swelling may also be present, and ascites are observed in approximately 10'1., of cases.
Most tumours are estrogenic due to function ing GCs , with symptoms dependin g on the
patient' s age and reproductive status. Young et at. (1984) also found that 82% of female
infants and pre-puberta l children present with isosex ual pscudoprccocity. characterized by
the growth of pubic and/or ax illary hair, breast development , uterine bleeding, vaginal
discharge, and accelerated somatic and skeletal growth. In adolescent girls and adult
women, the most common endocrine symptoms of juvenile GC tumours arc amenorrhea
and irregular uterine bleeding due to estrogen stimulation of endometrial hyperplasi a
(Young ct at. 1984). Rare cases of androgenic juvenile GC tumours resulting in
virilization have been reported (Young el at. 1984, Nomelini et at. 2007), suggesting that
the ability of the aberrant GCs toe onvert androgens to estrogens has been compromised.
Most tumours secrete excessive levelso finh ibin (Sivasankaran el a/. 2( 09),andserum
inhibin, E~, and anti-Mullerian hormone (AMII) are used as tumour biomarker s
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(Silverman and Gitc lman 1996).
Macroscopic examination has revealed that the average diameter of j uvcnilc GC
tumoursi s I2 .5cm in paticnts. Most tumours arc unilateral, although bilateral cases have
been reported. The majority of tumours arc uniformly solid and cystic, and usually vary
in colorf ro m yellow to gray-white to pink. Loca lizcd arcasof nccro ticor hemorrhagic
tissue may be present (Yo ung elal. 19 X4. Scull y el al. 199X). Microsco pically.juveni le
GC tumours show a distinct nodular or diffuse pattern of neoplastic CiCs. o ften with large
ova l orro und rud imentary foll icles containing eosinophilic orb asophilic fluid. ThcG Cs
and theca ce lls may be luteinized, and are present in a fibro thccomatous background . In
contrast to adult GC tumours. thc ju venile subtype shows GCs with immature and
hypcrchromalicnuclci (Young 2005). Mitotic activi ty is generally higher in j uvcnilc Gt,
tumours compared to the adult subtype (Scully et al. 199X. Young 2005) . In addition to
AMl l and inhibin, j uvcnilcGC tumours also show positive immu ne histochemical
staining fo r calrc tiuin, CD99. and FOXL2 (Matias-Guiu et al. 199X. McCluggagc and
Maxwell 200 1. A l-Ag ha el al. 20 1I ).
The majori ty ofj uvenile GC tumours arc diagnosed at FIGO (Intcrnational
Federation ofGynecology and Obstetrics) stage I; however. the disease is almost always
fatal at adva nce d stages (Yo ung el al . 19X4). Tre atme nt fore arly stage tumours is usually
surgica l dcbulking, with adj uvant platinum-based chemotherapy for advanced stage and
recurre nt cases. Tumours that recurt end to do so within three years, and mciastatic
recurrence is more common in thc j uvcnilc subtypc com parcdto adult GC tumours
(Young el al. 19X4. Gcct ha and Nair 20 I0).
IX
In theabseneeofae leargeneticctiologyforj uvenilcGCtumours. lhe abi lity to
predict susceptibility. accurately treat both primary and recurre nt cases. and estimate
patient survival is severely hindered . The know ledge that ju ven ile GC tumours initiate in
infants and young girls with an intact ovarian reserve prior to normal fol licle recruitment.
as well as the absence of the somatic mutation in FOXL2 reported in adu lt CiC tumours.
suggests that the two subtypes have diff erent etiologies. To defin e the genetic
determinants responsiblef()rt he initiationofthesej uveni leG C tumours. researc hers have
used model mammal ian systems forgenetic analyses.
1.3 Animal Model s of Granulosa Cell Tumuurigenesis
Sex cord-stroma l tumo urs arc the most com mon spontaneo us ovarian neoplasms
affe cting laboratory rodents. includ ing mice. gerbils. rats and guinea pigs (G rcc nacrc
2004. Thayer and Fostcr 2( 07). GC tumours occur at variable frequencies in different
inbred strains of mie e. partic ularly in aged mice. CE/Wy.l inbred mice arc naturally
susceptible to GC tumours. with 34%,of fema les affec ted by 22 months (mo: Dickie
1(54) . Aged NZC/I3I inbred mice also spontaneously develop CiC tumours at a 33'1.,
frequenc y (Bic lschowsk y and D'Ath 1973. Geary 19X4). Furthermo re. aged CF- I and
C311/11eNctr inbred mice are spontaneouslys useeptibie to ovarian tumours at 17% and
37% freque ncies, respectively. although tumour subtype classifi cations have not been
repor ted (Bres low et al . 1974. Frith e/ al. 19XI). Despi te the abundance of mouse strains
spontaneously affecte d byG C tumours. no genes conferring resistance or susceptibility
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have yet been identified. Furthermo re. these late-onset GC tumour models arc observed
ala time when the ovary is at or ncar follicle depletion, and as such arercflcctiveofthe
adult GC tumour condition rather than thej uvenileco ndition.
In addition to the spontaneous models ofGC tumo urigcncs is. a number of models
have been engineered through genetic alterations of oncogenes and tumour suppressor
genes. genes critical to normal endocrine function . und/orgcnc s expressed exc lusively in
ovarian GCs Crable 1.1). Mice null for lnhihi n alpha (Il1ha ) lose the normal negative
feedback regulation requ ired to suppress FSl l,a nd90'i{,of animals deve lopSCSTsas
early as I mo of age (Matzu k ct al. 1992). Targeted expression of the Simian virus 40 Too
antigen under the control of the lnh a promoter in ovarian stromaI cells results incomplete
GC tumour pcnctrancc in mice between 5 and 7 mo (Rahman et al . 199X). Risma ct al.
( 1995) introduced a transgenic L11[i-subunit into fcmalc micc. whichres ultedi n an
increased L11half-lite and subsequently elevated levels of serum testosterone (T)and E2•
GC tumours develop in 100% of these transgenic mice at 5 mo. albeit in a strain-
dependent manner. suggesting the influence of additional modifier genes (Keri ct al.
2( 00). Danilovich et al . (200 I) found that half of female mice null for the FS I I rece ptor
(I'\hr) gene spontaneously develop SCSTs by 12 mo. Ilomozygous knockout of the
Fanconi anemia, comp lementation gro up /)2 iFa ncd ? ) gene with heterozygosity for the
Transf ormation rela ted prot ein 53 (Trp53 ) gene results in tumours with GC components
in 30% of mice aged 14-15 mo (Il oughtaling et al. 2( 05). 129P2/0 lal lsd and 129/Sv
mice that are heterozygous fo r the Multipk: endocr ine neoplasia I tMen! ; gene develop
tumours in mult iple endocrine organs. including SCSTs. with 50% affected by 19-26 mo
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Ta ble 1.1 Ge netica lly eng ineere d mouse mod els of sex cord-stro mal tumo urs. KO : knockout
T umour Af fected ChI' Loca tion Na ture of GC Tum our
T umo ur Refer en ce
T yp e Ge ne (mo use) Mutation Frequ enc y
Onse t
mixe dSCST In17a KO 11110 90 % Matzuk elal. 1992
KO
mi xed SCST Faned2 6 14-15mo 30'% Hou ght ali ng el a l. 2005
(Trp53 he terozygous)
GC Lhh 7
Tr ansge nic
5 1110 100 %, Ker i et al , 20 00
Ul li-subunit
GC Smadl /Smadi 8/ 13 Dou bleKO 3 1110 100% Pangas et al. 2008
Co nstit utive
GC Ctnnb I 9 7.5 1110 57 % Bocrboorn et al. 2005
ac tiva tion
mixe d SC ST Fs17r 17 KO 12 1110 50 % Danil ovich el a l. 20 01
mi xed SCS T Men I 19 Il ctc rozygou s KO 12-26 1110 0-50 % l3ertolino el al. 2003
(Bertolino et al. 2003). Finally, the targeted mutation of genes specifically in ovarian
GCs has been accomplished using cre recombinase expression drivcn by theA ;'vll /
recc'/Jlor l.l1Je 2 (A mh r2) gene promoter. Boerboom et al . (200R) utilized this system and
found that GC-targeted constitutive activation of' [f-catenin transcription factor (Ct llllh/ )
results in GC tumours in 57''Ioofmiceby 7.5mo. Conditional double knockout of the
TGF!3 family members iv/A D hom ol og / tSmad l ; and Smad5 in GCs via the A m hr 2
promoter system resulted inG Ct umour deveiopment in mice by3 mo with compiete
pcnctrancc (Pangas et al . 200R).
It is evident that deletion of tumour suppressor genes or transcription factors
important for(iC growth control leads to highly predictable tumourdevelopment. in a
species inherently susceptible to SCSTs. Given the wealth ofin formation obtained to
date from the study of thc mouse ovary as a model fo r human ovarian physiology, it is
fair to speculate that these proteins could play a role at some point duringG C tumour
initiation or progression in human patients. At the level of genetic mutation. analysis of
Trp53 . Fshr and lnh a have not revealed GC tumour susceptibility candidates in adult-
onset human GC tumours (Watson ct al. 1997, Fuller et al. 199R, Ilorny et al . 1999 ),
although epigenetic mechanisms that may down-regulate their expression have not been
reported. For humanadultG Ct umours. a specitic, somatic mutationi n theFOX L2 gene
is the strongest associative mutation reported to date. yet forjuvcuilc-onsct Gtl tumours.
little to no genetic information is available. This research thesis has focused upon a
spontaneous model llJr juvenile-onset GC tumour development in an inbred mouse strain,
as a means to dcfine a genetic locus that confers susceptibility toG C tumour initialion at
a pre-pubertal stage in the presence of normal endoc rinological stimulation. and provide
new insight to the pathways that drive j uvenile-on set GC tumourigcncsis.
1.3. 1 T hc SW R/ Bm Mo use Mo dc l of .Juveuil e GC T u mourigen esis
The SWR/ BI11 (SWR) inbred mouse strain and its related recombin ant inbred and
congcn ic derivativ es arc unique in their heritab le and spontuncous Gt. tumour phenotype
thataffeets :sYY.,toa pprox imately 2S%of the young fema le population. dependingon
strain background (Beame r ct al. 19R5). The C1 C tumours first arise dur ing a restr icted
initiationwindow at 3 t04wk ofa ge. as pre-neo plasticblood-filied follicles that arc
macroscop ically visible on the ovarian surface (Ten nent et al . 1990). Those females that
progress throug h the pubertal transition unaffected remain tumo ur-free. retain fertili ty
with average litter sizes, and age normally without the dcvclopm cnt ofothcrpri mary
tumour s. The foll icular lesions found at 3 to 4 wk arc composed of degenerating oocyics
surrounded by a large t1uid- or erythrocyte-filled antrul11 lined byi rregular masses of GCs
and hypertrophied theca cells. Within oto Rw k. thetul11oursprogresst o ahighly
vascularized. cystic or hemorrh agic mass hom ogcnou sly cornprised of C1 Cs and enclosed
within the ovarian bursa. with occasio nal luteinized or necrotic areas (Bcamcr«/ al. 19RS.
Tennent ct al. 1990 ; Figure 1.0). The mouse GC tumours may be unilateral or bilateral.
and their malignant potential has been demonstrated by tumour occ urrence in both
ovaricctomizcd und intact transplant hosts that leads to death within 3 to S mo (Beamcrr -r
al. 19R5). Furthe rmore . Tennent et al. ( 1990) found 42% of mice with GC tumours aged
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Figur c 1.6 Bilateral GC tumours isolated from a gcnctically susceptible female
The tumours and uterus were removed at Xwk. The normal ovaries and uterus from a
littenn ate are shown for comparison.
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6 t09mo had metastases in major abdominal and thoracic organs. particularly the renal
lymph nodes, liver, and lungs. The mouse GC tumours secrete high levels of estrogens
and inhibin. mimickingt heir humanj uvenileG C tumour counterparts (Bcamcrcr n/ .
1988'1. Goczc et al. 1997). Excessive estrogen output from themouse GC tumours is
reflected in significa ntly increased estrogen-respons ive uterine weights and high
percentages of cornified vaginal cells (Bcamcrc/ al. 1988'1). as well as the suppression of
the contralateral ovary. which ceases ovulation ( l3eamer c(al . 1985). Mice withCiC
tumours have decreased levels of hypothalamic GnRIL pituitary FSII and l.l L and scrum
FSIL progesterone. dihydrotcstosrcronc (DIIT) and T (Beamer 1986). This unique and
heritable trait of early-onset GC tumourigcnesis occurs at puberty.priort o the depletion
of the ovarian reserve, and shows numerous parallels with the human juvenile condition:
therefore. theS WR mouse is a promising spontaneous animal model fort he identification
of genes involved in the initiation ofG C tumours in infanis and young girls.
Spontaneous GC tumour appearance in SW R mice is a hormone-sensitive trail.
Tumour grafiing studies have determined that an intact IIPG axis is required for GC
tumour developmen1. such that transfe r ofpre-pubertal, gencticalIy susceptible ovaries to
host mice that are hypogonadal and incapable ofsex stcroid production do not support
GC tumour development (Bcarnc rc r o/ . 1993). Inth e intact SWRfcmalem ouse. tumour
frequency is significantly increased with exogenous trcatmcnt oft hc functional Ll l
analog human chorionic gonadotropin (hCG). as well as downstream androgens
dchydroepiandrostcronc (DIIEA) and T synthesized by thecal cells in response 10 L11
during the pubertal transit ion (l3eamer c( al . 1988'1, Tcnncm cr o/, 1993, Dorward er o ".
25
1007 ). In accordancc with the lack o fspontancousG C tumour deve lopmen toutsidethc
restr icte d susceptib ility w indow . post-puberta l trea tment wit h these hormones does not
stimulate GC tumour initiation (Beamer (' I al. 1993) . Furthermore. sho rt-te rm exposure
to E2 before, but not utter. the appea rance of pre -nco plastic follicul ar lesions su ppre sse s
GC tumour inc idence (Dorwa rd (' I al. 1007). indicating that thc win dow of tumour
initiati on ove rlap s wit h that of tumour prevention in the mouse mod cl. T his prec ise
ho rmo nal regu latio n su ggests that the fir st pube rta l L11 wave and subsequent dow nstream
and roge nic sig na ling stimulates GC tumou r in itiation. and supprcss ion of initiati on by 1:2
occ urs du e to the inhibi tio n ofL l l release fro m the ante rior pitu itary.
Genetics
The trai t o f'j uv cni lc-typc GC tumour appea rance is pol ygen ic in SW R mice . and
mul tiple autosomal and X-linkcd loc i influence GC tumour in itiation (Ta ble 1.1 ). To
ove rco me the issue of low pcnctrancc in the mou se model. ini tia l e ff orts to identify thesc
loci invo lved incred ibly high numbers of anima l examination s. Geno mic loc i that
showed significant link age to spontaneous GC tumour initi at ion were named Granulosa
cell tumoursuscept ibilitvt Gct i loci . until suc h time that genes and a lle les a re ide nt ified .
T he GC tumou r su sce pt ibi lity genes func tio n autonomously wi thin the ova rian
compartment. as ovaries ob tained from genetica lly susceptib le fem ales develop (iC
tu mours whe n tran s ferr ed to endocr inologica lly norm al. pre-pub ert al fema le hosts that a re
genetica lly resistan t toGC tumo ur deve lopme nt (Bca mc r r-ro/. 1993). Desp ite the d rastic
16
Table 1.2 Autosomal and X- linked loci associated with GC tumour su sceptibi lity in
SW R mice
Loc us C hI'
Gel l
Gel] 12
cas 15
c.«
cas
Gel6
Gel ?
cos
ce» 1.3
Map ping Cross
Reference
l' artn cr Stra ins
S W RISJL I3cam cr el al. 19XXb
SW RISJ L I3camcr el a l.1 99X
S WXJ-9/C AST Dor ward el a l. 2005
S W RIS JL !3cam cr el ll l . 199 X
S W RISJ L I3camcr el 1l1. 199X
SW RJSJ L I3cam cr el lll. 199X
SW R/C AS T Do rw ard el lll. 200 .3
S W RIS J L I3camcr el 1l1.1 99X
SW R/C AST Dor ward eI 1l1. 200.3
S WXJ-9 /C AST Dorward el1l1. 20 05
S WX J-9/C AST Dorw ard el 1l1. 20 05
S WXJ-9/CAST Dorw ard el al. 20 05
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effect observed in females, no disccrnablc phenotypic consequence of the GC tumour
susceptibility alleles in malcSWR mice has been observed .
Although GC tumour susceptibilit y is a comple x trait involving multiple
hereditary loci. as igniticant body ofgen etic evidence supports thc Gelllocusondistal
Chr 4 as fundamental for spontaneous tumour initiation , with susceptibility alleles
contributed by the SWR strain (Gell sl'"). Gct l has been consistently associated with the
spontaneous GC tumour phenotype in three independent mapping crosses. Beamer et al .
( 1988b) generated 14 recombinant inbred (RI) SWXJ strains (SWXJ-I through 14) from
SWR and thc naturally GC tumour resistant inbred strain SJLl8 m (SJL), and found a
significant association linking both spontaneous and androgen-induced (,C tumour
occurrence with SWR-dcrivcd distal Chr 4. A second mapping cross using (SWR x
SJL)F2 mice examined spontaneous (,C tumour frequenc y, and confirmed the importance
of thcGel l locus, placing it within thc vicinity of thcs implcs cqucncc lcngth
polymorphism (SSLI') deoxyribonuc leic acid (DNA) marker f)4Mil 232 with high
significance (Beamer ct al . 1998). Finally, to improve mapping resolution and for
experimental replication otsu ggcsicd autosomal determin ants rclutcd to spomancous
tumour initiation , a third mapping cross between GC tumour susceptible SWXJ-9 mice
and the GC tumour resistant Castancus (CAST) mouse strain was performed using an
N2F [ backcross strategy. The CAST strain is a common mapping partner in mouse
mapp ing crosses, given its genomic divergence from more common laboratory mouse
strains and the subsequent potential for higher genetic resolution (Pctkov el al. 2004 ).
Thc rcsult oft hc Nyl: backcross study provided further cvidcnccf \)rlinkagcb clwccn
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D4Mil232 and the spontaneous CJC tumour phenotype (Dorward el al. 2005). with the
susceptibility allele contributed by the SWR genome. These mapping crosses suggested
associations between the CJC tumour phenotype and numerous other autosomal
susceptibility loci in addition to Gct l ; however. a lack of consistent linkagc ofa nyother
loci over mult iple mapp ing crosses suggest that theirintluencc is contingent upon strain
background and potential epistatic interactions.
lt was recognized carlyo n that the androgenic stimulation of the prc-pubcrtal,
genetically susceptible SWR mouse ovary could significantly increase the numberof
females with CJCtumours (l3eamere l al . 19XXa). lnbrcd Sw k fcmalc micc havc a
spontaneous CJC tumour frequency of ::;I'X,. which increases to ~20% upon DIIEi\ or T
treatment at puberty (Figure 1.7; l3eamer el a l. 1993). Given that DIIEi\ is an upstream
metabol ite of the androgenic steroids (Figure I.X). Te nnent elal. (1993) examined
whether DIIEi\ supplementation was simply a substitute fix T administration. An
interesting phenotypic segregation arose between the eight lines of the S\vX J RI strain set
that maintained the Gel l swallele. CJC tumour frequencies from four RI strains with low
spontaneous tumour incidence were significa ntly increased with either DIIEi\ or T
exposure. whereas another group offo ur " DIIEi\ -dependent RI strains" that were
previously resistant to spontaneous CJC tumour initiation only responded to DIIEi\ . and
not T. treatment. As a result. Gel t l 'w is described as a DIIEi\-r esponsive locus. and
DIIEi\ stimulation has been used to further map the region.
In addition to Gct l , two other confirmed. independent loci. Gct-! and Gu6 on ChI'
X. arc strong modifiers of CJCtumour susceptibility. and were identified using a
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Gctl Alle lic
Consti t uti o n
End ocr ine
Trea tm en t a t
Pu be rty
No ne
DHEA
DHEA
Biolog ica l
Outcome
nor m a l ova r ia n
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GC t um o ur
fre que nc y (S l %)
nor m a l ova r ia n
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fre que nc y ("-'20%)
norm a l ova ria n
de ve lop m e n t (100%)
Fig u r c 1.7 1mp act of th e all elic con stitution a t G et I and th e e nd oc r ine e n vi r o n me nt
o n G C tumour suscept ib ility in fem al e mi ce
Mice with G ct /,I'II' alleles have a natural (iC tumour frequency 01'< 1'%. which increases to
approximately 20%,when given DIIE1\ at puberty, Mice with Gct / ' arc completely
resistant toG C tumour dcvclopmcnt.cvcn when given exogenous DIIE1\.
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Estro n e ~17P-Estra d io l
Figure 1.8 The steroid hios ynthetic pathway fur the conversion ofsubstrate
cholesterol to androgen s and estrogens
DIIEJ\ is converted to androstenedione by 3IJ-HSD, which is converted to T in a
reversible reaction catalyzed by the deh ydrogenase/ redu ctase enzyme 17IJ-IISD. 171J-
IISD also eatalyzes the reversible eonversion of estrone to E2. whieh ared erived from the
androgens via arornatasc activity. The synthesis of Dl lT from T is catalyzed by the
enzyme Sn-rc ducta sc .
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recombinant progeny lest mapping strategy (Dorward ct al . 20(3 ). Howeve r. the capac ity
for Gct« and Gcui to support GC tumour initiation is dependent upon the presence of the
Gc l l SII"allele. Mapping of these two X-linked loci using SJL and CAST as mapping
partners has been accelerated by the high (iC tumour frequency and parent-of-origin
effect associated with the paternally inherited SJL (GcI4J ) allele. To date. Gct-t and Gct r.
havebecn mapped to a high resolutionofl .345 million base pairs (mc gab asc: Mb) and
1.0 19 Mb. rcspectively (Dorward el al. unpublishcd). although at present thc idcntities of
Gct-t and Gc l6 remain undefined . Given the role of androgens in GC tumour initiation .
the Androgen receptor (Ar) gene has been considered and remains a primary candidate
for GCl4 identity: however. no nucleotide differences arc evidentintheprotein coding
region sequence of /lr in SWR and SJL mice compared to C57BLl6 (86) and I3ALB/c
reference sequences (Dorward et al . 20(3 ). The strong paternal parent-of -origin effect
associated with the X-linked loci suggests epigenetic regulation. and that allelic
differen ces at the level of gene expression rather than protein sequcncc undcrlic thcir
modifier activity.
The required contribution ofSWR-derived suseeptibilit y alleles at Gcl/to support
spontaneous and hormone-inducedGC tumourigcncsis.u s well as its consistent
identification from three independent mapping crosses. cement s the GCl t \'1I"allele as the
fundamental driver forthi s comple x. developmentally restrieted phcnotypc. No other
inbred mouse strains contribut e Get I alleles that support GC tumour suscept ibility even
with androgen treatment. indicating that a genetic determinant unique to SWR contributes
to tumour initiation. and the GCl t 'ill" allele should be identifiable by genetic comparison to
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other strains (l:3eamer eta/. 1988b).l\comparisono f the mousec hromosomal locat ions
of genes associated with sporadic adult-type human GC tumour appearance (F OXL2 (Chr
9), STK I I (Chr 10)) or engineered mouse models ofG C tumourigcncsis (e.g. Ctnnb l .
1/1//(/) do not overlap with the distal Chr 4 region (Tables 1.1 and 1.2). suggesting the
GetI gene is a unique entity impacting upon GC tumour susceptibility. l lowcvcr, this
does not discount the possibil ity that the tumourigcnic pathways initiated by Gct l may
directly impact upon these reported pathways fo r GC tumourigcncsis, Resolut ion of the
identity of Get l SIJ'in the mouse model will provide candidates for translation into the
human condition of juvenile GC tumourigcncsis,
Stra teg ies to Positionallv Clone Gct l : Prel iminary Work
In the field of mouse genetics. a common strategy to resolve importantg enetie
loeii ndependently fh 1l11 0therl ocith atunderly polygenictraitsi sth e creation of a
congenic strain. Congenic strain development begins with an outcross between two
inbred strains. followed by backcrossing to the inbred paternal strain for 10 or more
generations. while maintainingh elerozygosity at a selected locus (Silver 1995). This
breeding pattern effectively results in a "s wap't oft hc allclcs at a part icu larlocus trom a
donor strain into a recipient strain background, which after 10 generations of
backcrossing is 99.8'X, homozygous (Figure 1.9; Flaherty 1981). The resulting congenic
strain is maintained by brother-sister intcrcrossing. Preliminary work has been completed
to isolate Get ! in a congenic strain. SWR.S.lL-X.CI\ST -4-T (Line 4-T). Line 4-T is in
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CAST SWR
Figure 1.91soiatillg GctJ ill a cuu geni c stra in
A schematic representat ion of the relative contributions of donor (CAST) and recipient
(SW R) alleles at sequentia l generations of backcrossi ng. Cell ca lleles arc swapped with
Cel I oi' ll"alleles into an SWR background which is 99.R'% homozygous after 10
generations. Black: SWR alleles: white: CAST alleles: checke rboard pattern:
heterozygous alleles. Adapted from Hahcrty t lvx l ).
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fact a double eongenie stra in and maintains an SWR genome with the except ion of two
distinct genomic segme nts: the distal segmento fC hr4and the middle port ion ofCh rX.
The ChI'4 region harbours a homozygous segment of the CJCtumour resistant CAST
inbred strain genome. from DNA marker D4Mil31 ( 106.7 Mb) to D4Mi l256 (154 .3 Mb).
fix a total seg ment swap of approx imately 47 Mb inclusive of the D4i'v1i1232 marker. To
ove rcome low GC tumour penetranee in the mouse model. Line 4-1' also carries the Ge14!
allele fix increased GC tumour appearance . Line 4-1' mice arc resistant to ( ;C tumour
deve lopment both spontaneous ly and follow ing puberta l exposure to eitherof the
androgens DIIEA or T. which confirms the swa p of Gel / . alleles for Gel ( , II' alleles and
thus makes Line4-Tasuitab leeongenie line for further mapp ing (unpublished data).
Loss ofthe GC tumour phenotype in Line 4-1' also confirms the requirement of Gel(""
alleles for tumour appeara nce even in the presence of theCJC tumour permissive Get4.1
alle les .
Followi ng the development of Line 4-T. informative recomb inant subeongenie
lines were create d by fragmenting the large region inclusive of Gel I . breeding to
homozygosis. and testing tor susceptibility to (;C tumour initiatio n. Ilomozygous Line 4-
T individ uals were bac kcrossc d to produce heterozygotes at Gct l , »nd subscquc nt
baekero ssing genera ted N2FI mice with unique combinations of the CAST and SWR
gcnomcs across the Gct l locus via meiotic recom bination. The 10 bestrepresentatives
covering the GCII locus were chosen fix further intere rossing to produce homozygous
individua ls at Gct l , which formed a series of nested subco ngcnic strai ns (SWR.SJL-
X.CAST -4- 1 through 10; Figure 1.10). Nine of these lines were successfu lly creat ed and
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F:(h eterozygo l e)x sWR.s Jl-X
Series of GetJC/GctlCNesl ed
SubcongenicUnes
Figure 1.10 C re ating su bconge nic strains to map Get !
N,F: (hete rozygole l lnterc ross
An N2F 1 backcross breeding scheme was utilized 10 generate unique combinations of the
CAST and SWR gcnorncs across the Gei l locus by meiotic recombination. Informative
mice were chosen for furth er breeding to create a series ofhomozygoux ncstcd
subcongcnic lines.
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tested for GC tumour incidence following pubert al exposure to DIIE1\ to increase trait
pcnctrancc. using a group sizc( n) of 50 animals. Six lines had the most informative
combinations of thc SW R and C1\ST gc nomcs to resolve thc Ge l / iocus and arc shown in
Figure 1.11. This first round ofp henotypic mapping has been completed, and resul ted in
a refined Gel l interval of6.48 Mb between marker s 1J4Mil13 ( 142.09 Mb) and 1J4M il 49
( 148 .57 Mb).a rcgion that contains approximatcly 300 pscudo-. protein codin g. and non-
coding RN1\ genes. The Line 4-T recombinant subcon gcnic lines that retain GC tumour
resistance indicate that no other C1\ST genomic clements remain in the Line 4-T genomic
scgmcnt that rcprcss C;C tumour susccptibility. and that thc Gel I locus indcpcndcntly
controls GC tumour initiation in congcnic females. The successfu l development ofthe
recombinant subcongcnic lines also suggests an absence of chromosoma l inversio ns
within thc Gel/intcrvaLwh ichwould supprc ssrccomb ination acro ssthc rcgionand
interfe re with the congcnic mappin g strategy. Line 4-3 is homozygous for a smaller
portion of the C1\ST genomic segment on Chr 4 than Linc 4-T. from DN1\ marker
1J4Mil3 1 (106.7 Mb) to 1J4M il 362 ( 148.7 Mb), and reta ins resistanc e to both spontaneo us
and androge n-induce d GC tumour incidence. 1\ second round of pheno typic mapping has
been initiated with Line 4-3 as the starting dono r for recombin ation betwee n Ge l1"and
Gel /"\'11"alleles, Line 4-3 will be used in the same way as Line 4-T to generate a series of
ncstcd subcongcnic Iincstoimprovcmappingrcsolutio n at Gct l . This refined interval
will bc the focus ofexpression and seque nce exa minat ion fort he iden tifica tion ofa gcnc
with shared identity with Gct l . 1\ sununury ofthc inbred, congcnic and recombinant
subcongcnic lines including their alleles at Get I and the X-linkcd loci Ge/4 and Gctt: is
shown in Table 1.3.
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Chr 4 pos itio n (Mb)
• CAST
o SW R
DNA marker
~
D4Mitlo D
D4Mit148 0
D4Mit2 83 0
D4Mit13 0
D4Mlt232 0
D4Mlt206 0
D4Mlt129 0
D4Mit49 0
D4Mit 362 0
D4Mit127 0
D4Mit14 0
D4Mlt190 0
D4Mit6 3 0
D4Mit208 0
D4Mit256 0
Subcongeni c li nes
c: "r u: ~ O?
Ii Ii Ii Ii 0 134.23
• ••• 0 136.70
• ••• 0 138.48
• •• 00 142.09
• • DOD 144.65
• • 0 00 147.25
• • 0 00 148.30
• 0 0 0 0 148.57
• 0 0 0 0 148.72
o 0 0 0 . 149.30
o 0 0 0 . 149.50
o 0 0 0 . 150.08
o 0 0 0 • 150.34
o 0 0 0 0 • 152.50
o 0 0 0 0 • 154.36
Gcr1
interval
(6.48 Mb)
# females with GC tumours +
# females examined
GC tumourfrequncy( %)
0 00 5 8 10
34 51 50 45 43 62
000 11.118.6 16.1
Figu re 1.1 1 C hr4 hapl ot yp es ofSWR and Line4-Tsu bco nge nic mou se lin es a t (;('11
Females from thc Line 4-T recombinant congcnic lines 4-5. 4-6. and 4-8 have a
significantly higher GC tumour incidence than Linc 4-T and 4-2. 4-3. and 4-4 females.
Thus lines 4-5. 4-6. and 4-8 carry the Ce l I sII' allele, whereas lines 4-2. 4-3. and 4-4 do
not. and Gel/ rcsidcsinthc approximatcly 6.48Mb intcrvalbctwccn D4ivfi l 13 and
D 4A1i1129. +: GC tumour susceptible: -: (iC tumour resistant: black boxes: CAST alleles:
bluc boxcs:S WRallc lcs;yc llow rcctanglc: thc Gel/intcrva l.
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1.4. Hypoth esis and Research Obj ecti ves
Hypot hesis:
/\ unique genetic determinant is present within the Geil loeus in SWR mice.
which supports the initiation ofovarianG C tumours in an androgen-rcsponsivc and
ovarian-autonomous manner during the mouse pubertal transition.
Research O bjectives:
I) Completion of the phenotype assessment and tine mapping for the genomic
boundaries of six rccombinant subcongcnic lines derived from Line4 -3. to reduce
the Gct l candidate gene interval
2) Qualitative assessment of the genes in the refined Gct l interval for expression in
the ovary
3) Evaluation of priorit ized candidates for shared (Jell identity. based on known
biological roles and the qualitative assessment. by quantitative expression and
sequencing analyses
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2. Materia ls und Met hods
2.1 A n lma l Hu sb an dr y
Animal Housing
All mice were maintained in a facility operated by Animal Care Services of
Memorial University of Newfoundland in accordance with the guidelines of the Canadian
Council on Animal Care. Mice were housed under a 12:12 h light/dark cycle and
provided with Laboratory Autoclavable Rodent Diel SOIOfood (27.S'!!" protein. 13.5'Y<,
fat. S9% carbohydrate : I'MI Nutrition International. Richmond. IN) and water 11£1 libitum.
Animals were weaned at 20-23 d of age and housed in groups of two to t'ivc animals per
cage in I I" L x T W x S" II rodent cages containing l3ed-O-Cobs'" corn-cob bedding
material (The Andcrso ns, Maumee. 0 11). All animal procedures were approved by the
Institutional Animal Care Committee of Memoria l University of Newfoundland.
MouseStrains
Line 4-3 was used in the generation of new recombinant subcongenic lines as it
contained the smallest defined Get I interval at the start of the second round ofp hcnotypic
mapping. The lines gcno typcd and brought to homozygosity before phcn o typ ing. SWR
and Line4-T were used forall serum. candidate gene sequencing. and gene express ion
analyses. Gc notyping assay standards were: SWR. Line 4-T. and (SWR.SJL-XS x Line
4-3) fi rst filial generation (Fj) hybrid.
4 1
Surgical Capsule Implantation
The Line 4-3 recomb inant subcongcnic mice were treated with DI II:I\ to increase
trait pcnctranc c to facilitate phenotypic mapping, and SWR and Line 4-T mice were
treated with Dl lEl\ or acontrol treatment t()rthcquantitativc cxprcssion analysis. Mice
wcrcanacs thctizcd withi sotluranc(2-chloro-2-(di tluoromcthoxy) - I. I. I-tritluoro-cthanc)
(Bax ter Corporation. Mississauga. ON) and subcutaneously implanted with a capsule via
a small dorsal incision at 3 wkofagc. Capsules wcrc cornposcd of lOmm long Silastic
tubing ( 1.9X 111111 inner diameter: Dow Corning. Midland . MI) filled with approximately
150 mg of99.5'X,pure powdered DII EI\ (S-nndros tcnolonc-J fi-o l- l Zvonc: Cataloguc ID
I\X500-000.S tcraloids lnc., New po rt, RI) and wcrc scalcd at cach cndwi th a 3nll11 glass
bcad dishcr Scicmific. Fairlawn. NJ). Contro l capsules were empty. Incisionswcrc
closc d using a v mm Autot. lip" stainlcssstccl woundclip( MikRon Preci sion Inc..
Ga rde na, CI\) . Mic e were subc utaneo us ly injected with 0.1 m l, 0.5 ng /m l, (5 mg/kg)
Rimadyl" (carprofcn: PfizcrAnirnal l lcalth, Kirkland ,QC) analgcsicpostopcrativcly.
Wound clips were removed from Linc4-3 rccomb inant subcongcnicmicc appr oximatcly
I wk after surgery . Illustra tions of thc phenotypic mapping and quanti tative expression
analysis treatment paradi gms arc shown in Figurcs 2.1 and 2.2. rcspcctivcly.
2.2 Phen otypi c Ma pping
Animal Examination and Statistical Analvsis
Micc were cuthanizcd with CCh gas at Xwk ofage. and GC tumour devel opment
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An imal Age
Owk 3wk 8wk
DHEACa psuie Implanted
--+-------1
Necrops ied
j
Ovaries M acro scopically
Examined and GC Tumou r
Freq uency Reco rded
Figure 2. 1 Ph enot ypi c mapping paradi gm fur GC tumour susce ptibility ve rsus
resis ta nce
Line 4-3 recombinant subcongcnic mice were subcutaneously implanted with a Dll EA
capsule at 3 wk of age. A ftcr S wk of treatment (at Xwk of agel. mice with present and
intact DIIEA capsules were necropsied and their ovaries were macroscopically examined
for the presence of GC tumours. Tumour frequency was recorded in those mice with
present and intact DIIEA capsules.
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Anima l Age
Ow k 3 w k
Capsule Imp lanted
/\
Empt y
4wk
I
Necropsied
l Serum1----. Collected
Figure 2.2 Sa mple co llect ion par adi gm for qu antit ati ve ge ne expressi on in the ovary
a nd seru m a na lys is
SW R and Linc 4-1' m ice we re subc utaneous ly impl anted with a DI IEi\ or control ca ps ule
at3wkofagc. i\ tic r l w k o f trca tmcnl (a I 4 wkofagc ). miccwcrc nccro psi cdand
who le ov aries from mice with pre sent and intac t DI IEi\ cap sulc s were co llected and
pool cd . ScrLIm sampl cswcrc collc ctcd a tthctimc ofnccrop sy.
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was asscsscdbymacrosco piccxaminationofthcovaricsi nmiccwith prcscnt andintact
DII EA capsule s , Mice w ith pa lpable GC tumo ur masses were nec rop s ied ea rlier than X
wk . T he min imum sa mplc s izc of' n v Su indiv idua l ani ma ls perrecombinant
subco ngc nic line was dete rm ined through powe r calcul atio ns (T ype I er ror probabi lity. a
= 0.05. Type II error probab ility. I)= 0.20 ). base d on an expec ted GC tum our frequenc y
ofapproxima te ly 20% in S W R mice supplemented w ith DII EA at pub erty. and O'X, in
m ice w ith CAST alleles at Gct l . GC tumour frequ encies were co mpare d by chi-squ are
test (P = 0.( 5) us ing Ciraphl'ad Pri sm ve rsion 5.00 for W ind ow s (Gr aphl'ad Softw are .
Sa n Diego, Culi fomia, USA. ww w.graphp ad .com) .
GenotypicMapping
Gcnotypi ng marke rs used we re SS Ll's and si ng le nucleot ide po lym orph ism s
(SN l's) empirical ly determ ined to be polym orphic between the S W R and C AST
gcnorncs. SS Ll's and the ir prim er sequences we re annota ted in the Mouse Gen om e
Datab ase (MG D; Blake et al. 20 I I; www .informat ics.j ax.org ). o r identi fied and de s ign ed
in-hous e (Append ix A) . SN l's were anno ta ted in the Na tiona l Ce nte r for Biotec hno logy
lnf ormation (NC BI) Si ng le Nuc leoti de Po lym orph ism Database (dbSN I') Bu ild 132
(S hcrryelal. 200 1; ww w.ncbi .nl m.nih .gov/p roj cct s/ SNI'). o r idcntif i cd du rin g
prclim inary candid atc gcnc scqu cn cing. Bccaus c thc Sw k stra in hus not bccn rc-
sequenced, annot ated SN l' s were chose n on the basis ofd ifferen ces betwe en CAST
alle les and the alle les ofothercommon inbre d stra ins . part icu larl y Sw iss-derive d strai ns
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which arc phy logc nctically rela ted to SW R (Pctkov et al . 2(04). SSlP mark e rs were
co nfirmed fro m tail DNA and assessed for allele size by horizont a l agarosc gel
electrophoresis, whereas SN I' mark ers were amplified from kidney DNA an d assessed for
nuclcotidcchangcsbycyclcscqucncing. Newly reco mbina nt linc4-3 subcongcnic
indivi dua ls and thei r in itial hom ozygou s progen y were tested agai ns t the panel ofSSlP
and SN P mark ers to es tablish C hr4 hapl otyp e patt ern s. SN l's were identified in at leas t
tw o ind ividua ls from ea ch l inc 4- 3 rccombina nt subco nge nic line , Primcr scqucn ccs for
annotat ed SS l l' gcno typing mark e rs were obt aine d from MGD : all ot her gcno typing
prim ersequences were des ign ed us ing Primcr3 versio n 0.4 .0 (Roz en and Ska lctsky 2000:
www.frodo .w i.mir .cdu /prim cr.I) . Gcnoty ping ma rkcr primc rscqucnccs. SS LPa llc ic
siz cs for CAST and SW R. and the ir location s on C hr 4 arc sho wn in Ta ble 2.1 .
2.2. 1 Genotyp lng by Simple Sequence Length Polym orphisms
Tail Tip Biopsy and DNA Extraction
Approximately 2 nun oftissuc was removed from the ta il tip us ing scissors upon
necro psy or before m ice reac hed 4 wk of age, Tai l sam ples we re placed in a 1.5 ni l,
microcc ntrifugc tube wi th 500 II I of 50 mM so di um hyd roxide (13DI I Inc.. To ronto.
ON) . The tubes we re placed on a heat bloc k fo r 10 m in at 95 °C, after whi ch 50 ~l L of
Iris- I IC I pl l X.O(Sigma-A ldr ich Inc.. St. Louis. MO : Fisher Scientific, Fa ir Lawn . N.I)
was added . T he sa mples were ce ntri fuge d a t 10.000 x g 1()r 30 s.und 500 IlL of
superna tant was transferred to a 1.5 m l, microccntr ifuge tube. T hc DNA sa mples were
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Ta ble 2.1 SSLP a nd S~ I) genoty p ing ma rk er s. Primer sequences and location on Chr 4 arc shown (Ensemb l release 61 .
NC Bl m3 7). SS LP sizes were determined from hor izont al agarose gel elec tro phoresis . Gc no typing using SN P mar kers was
base d on multip le bp subs ti tutions at eac h ma rker and ca n be found in the res ults ' text. C: CAST; n/a : not applicab le; S: SW R
Mark er Forw ard Scqucncc t.S'e-G') Rcvcrsc Scqucncc t.S'<- B'j Ampl ified Region ofSym bo l Chr 4 (bp)
D4Af il/3 GCTGGTAGCTGG CTTTTCT C CA GA TGTTCCT A CTG CTTGG 142.094 .205- 142.094.293
D4Afi l/ 26 TGCACTTTTGAGATTG CCAG GT CTTTCCCT CT CCCT CCC 142.152.65R- 142.152.805 SSL P C > S
D4sjh/ 9 GTGGGGAGCA TGT CCTT A AA TGG GAGTGTGTA GCAGAGGA 142.633.317-\42.633.544 SSL P C >S
D4Afi l/ 60 A CTATGCTA A A CCA A CAATCT CCC CCG AG A A ACC T A A TCTT GA TG A 144.040.010-144.040.205
D4sjh/O GCAGAAATGG CA CAGGAGAT CCC AC A TTTGAAACCA CCT C 144.20R.R22-144.209.06 1
D4sjh9 GGACTGGCT CTGAGGAACAA GCCAAGCAG CTT CCT CTT AG 144.635.R4R-144.636.084 SSL P C <S
~ D4M il23 2 GC GTC ACCACAC TGC TC TT A CT CAG A GT CCCCTGGCC \44 .64 7.559-144.64 7.676 SSL P C >S
TGGTCA TGTGTGTCCA TGC A CTT CA TGTAGCCA GGTGGG 144.RI4 .R47-144.815.02\ SSL P C >S
CTT T A GGT A GAACTT CTT CCGTTTT GTG GC AG TGAAAC TT A TT CAACC 146.RI 5.3RO-14 6.RI5.4 79 SSL P C > S
TGAAGGCCT GA GTTAA TA CCT AG C TCA TCAA CT AAGTGACAAGGAAGG 147.251.45\ -\ 47.251.598 SSLI ' C < S
Nppb GAAGACA CCAGTGCA CAAGC AA TCCCCCA TCCTT CCA T AG 147 .360.003- 147.360.359
D4.\j h// CCACC A GG TC TGG A TA GC A T GCCA GGAAGGCT AG CA TAAA 147.540 .887-147.54\ .118
D4sj h / 2 TTTGGAGA CCA A AG A TGAGACA CTT TTCTGGCCT CT GACC TG 147.643.331-14 7.643.56 \ SSL P C <S
D4sjh 13 TC TGGTTTCT ATG CGTGTGC CGGG A T CCA T A TGGT AG TGG 14R.093.433-14 8.09 3.65 8
D4.\ /il/ 29 GTAA A TA CA CAACCA TAG AGACCTG C TG CCT GCCT A CTTGTGTTTG \4 R.297.26R-14 8.29 7.396
TTG CCTAGCA TA CCTG CA TG GCTG GGTTTGT GG CT CAG \4 R.572.905-14 8.573.054
sto red at-20 °C until assaye d.
Po lyme rase Chain Reaction
SSL P genotyp ing marker s were amplified by PCR usin g a Master Taq Kit (5
PR IME lnc., Gai thersburg, MD) from genomic DNI\ ex tracted from Line 4-3
recombinant subcongcnic mice ta il samples, and fro m SWR, Line 4-1' and (S W R.SJL-X5
x Line 4-3) F 1 gcnotyp ing standa rds . The followin g reagent s we re co mbined in a 0.2 mL
PCR tube (Bio-Rad Laborat orie s, l lcrculcs CI\ ): 7.3 ~IL of distil led wate r, I ~I L of 5X
TaqM aster PCR Enhancer heated to 65 °C , I u l, of l OX React ion Butle r, 0.2 ~I L of 10
mM dc oxynu clcot idc tripho sphatc s (dNT Ps) ( Invitro gen, Ca rlsbad, CI\ ), 0.22 u L of 10
uM forwa rd and rever se primers (Inte grated DNI\ Techno log ies , Cora lvi lle, 11\), 0.05 ~IL
of Taq D 1\ pol ymerase, and I u L of DNI\ templ ate . 1\ negative cont rol was incl uded
with each PCR with distilled water in place of DNI\ templ ate . The tube s were placed in a
Ven ti" 96-Well Thermal Cyc ler (Appl ied Biosystcm s Inc., Foster City, CI\) where PCR
wa s per form ed using the follow ing profile: 97 °C for 30 s; 39 cycles of94 "C for 15 s, 55
"C for 30 s, and 72 "C for 30 s; 72 "C lor 10 min. The PCR products were stored at 4 °C
until gel electroph ore sis.
Gel Electrophoresis
SS LP genotypi ng PCR produ cts wer e sepa rated by hor izont al elec trophoresis
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throu gh a 4% aga rose gel. PCR produ cts (9 .99 ul.) we re combined with 3 ul, of gel
load ing bu ffer (Bro mo pheno l Blue, Sodium Sa lt; EMD Millip orc, Billerica, MA) in a 0.2
mL PCR tube and mixed by pipettin g. The gels were com pr ised of 8 g of MetaPh orOO
aga rose (Lonza , Rockl and , M E), 20 m l, of l OX tris-bora te ethyle nedi amine tetr aac et ic
acid (E DTA) buffer (1'1312; 0.89 M tris, 0.89 M bor ic ac id [F isher Sc ientifi c, Fair Lawn.
NJ] , 0.02 M EDTA [Sigma-Aldrich Inc., St. louis, MO l) and 180 ml of dist illed wate r,
The gel mixture was boiled usin g a microwave, and afte r cooling wa s pour ed into a gel
electrophoresis chamber taped at both end s and containing loading we ll co mbs. After the
gel solidified the co mbs wer e remo ved and the PC R produ etlloadin gbuffer solu tion or 10
III of 100 base pair (bp) DNA ladd er marker (Bio Basic Inc., Mar kham . O N) were
pipc ucd into the well s. The gels were electrophoresed for 3 h at 120 V. after whieh the y
were post-stained with 10 mg/m l eth idium brom ide (S igma- Aldrich Inc.. St. l ouis. MO)
for approxima tely 30 min. The SSLI ' PCR produ cts were visualized using a U:Ge nius
GelVue UV transillum inator (302 nm ; Synge ne, Fred eri ck, MD ) and scored for alle le size
di fferen ces betw een SW R, CAST and F1 DNA standar ds .
2.2.2 Ge not yp ing by Sing le 'ucleotid e Polym orphism s
Kidney DNA Ext raction
DNA was ex tracted from single whole kidn eys homogeni zed on ice in 6 m L o f
iso tonic high pi I (l so-lli-pll ) buff er (0 . 14 M so dium chloride [BDII Inc.. Toronto. O N].
0.01 M tris pIl 8.4, 1.5 mM magnesium chloride [S igma -A ldrich , St. Louis. MO l) with
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0.1% Igep a l CA -630 (Sig ma-A ldrich, St. Louis, MO ) using a Doun ee homogenizer.
Lysa tes wer e tran sferred to a 15 m L ce ntrifug e tube (C orn ing Inco rporated , Co rning , N Y)
an d ce ntrifuge d at 800 x g for 5 m in at 4 DC. Supernatants were d iscar ded an d nuclear
pell ets resu sp en ded in 6 m L of Iso-I l i-pll Buffer wit h 0.1 % N P-40 . A 300 u l, a liquo t of
20 % so di um dodccyl sulfa te (Sigma-Al dric h, St. Louis, MO) and ISO ul, of 10 mg/mL
Protei nase K (Sigma-A ldrich, St. Loui s, MO) were added to the tub es, which were
imme diate ly and repe atedly inverted and pla ced in a wat er ba th at 37 DC fo r 3 h w ith
per iodic inve rsions . Fo llowin g incubation, 2 m L of 6 M so dium chlo ride was added to
the tubes , w hich were mi xed by vigorous inve rsio n and cent rifuged at 2,000 x g fo r IS
m in at roo m tempe ra ture (RT) . T he supe rna tant was tran sferr ed to a 50 mL ce nt ri fuge
tube (Corn ing Incorp orated , Com ing, NY) w ith a wide -bore tra nsfer pipette and the DNA
was pre cip itated by ov erlay ing tw o vo lumes of anhydrous 95 %. eth an ol (Co mmercial
Alcohols, Brampton, ON) . DNA wa s spoo led on a g lass rod, soa ked in 70% et hanol
(Co mme rc ia l Alco ho ls, Brampton , ON) for 10 min , and a ir dr ied ove rnight. T he dried
DNA was resusp ended in 600 flL oft ris- ED TA (TE; 10 m M tris pI1 8.0, ImM EDTA
pI I 8.0) and m ixed on a rot ator overnight. The D A stoc k so lut ions were diluted 1:9
DNA to distilled water and stored at -20 DC.
Polymerase Chain Reaction
SN P geno typing mar kers we re amplified by PCR using an Accupr imc" Kit
( Invi troge n, Car lsbad, CA ) from geno mic DNA ex trac ted from SW R, Line 4-'1', and Line
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4-3 recombinant subcongenic line mouse kidneys. Thc following reagents were
combined in a 0.2 mL PCR tube: 22.5 ~IL of Accuprimc'" Pfx Supcrmix, 0.25 ~IL of 10
uM forward and reverse primers, and 2 uL of DNA template. A negative control was
included with each PCR with distilled water in place of DNA template. The tubes were
placed in a Vcriti" 96-Well Thermal Cycler where PCR was performed using the
following profile: 95 °C for 5 min; 35 cycles 01'95 °C for 15 s, 55 °C for 30 s, and 68 °C
for 45 s; 72 °C for 10 min. The PCR products were stored at 4 °C until gel
electrophoresis.
Gel Electrophoresis
Successful amplification ofSN P genotyping marker amplicons was confirmed by
electrophoresis though a 1.5% agarosc gel. PCR products (5 ~IL) were combined with 3
~IL gel loading buffer in a 0.2 ml, PCR tube and mixed by pipetting. The gels were
comprised 01'0.75 g of agarosc (Sigma-Aldrich, St. Louis, MO), 5 mL of lOX TBE and
45 mL of distilled water. The gels were cast, loaded and peR products visualized as per
the protocol for SSLP genotyping markers (section 2.2.1.3). The gels were
electrophoresed for 30 min at 120 V.
PCR Product Purification
PCR products were purified using a QtAqu ick" PCR Purification Kit (Catalogue
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Number 28 106; Qiagen Inc., Mis sissau ga, O N) as per the man ufactur er' s sta ndard
protocol. Briefly, five vol umes of bin ding buffer to one vo lume of PCR pro duct we re
combi ned with 10 IlL sodium acetate (J.T. Baker Chemical Co., Philli psburg. J) and
transfe rred to a 2 m L filt er co lumn in a co llec tio n tube . After centrifugation, the flow-
throu gh was discard ed and 750 IlL of el ution bu ffer was adde d to the filter co lumn . Alle r
two seq uentia l centrifuga tions, the filter co lumn was tran sferred to a 1.5 mL
mierocentrifuge tube and 30 uL of distilled water was pipcttcd directly onto the filter
membrane, The tubes were centrif ugc d aftc r a I min incubation at RT, and the pur ified
PCR produ cts were stored at-20 °C .
Cycle Seque ncing
All cyc le seque nci ng reacti on s were carried out at the Gcno mics and Proteom ics
Facility, Core Research and Equi pment and Instrum ent Training Network, Memorial
University of Newfoundland, using a BigD yeQ!) Terminator v3.1 Cycle Sequencing Kit
(A pplied Biosystcm s lnc., Fos ter Ci ty, CA) . The foll ow ing reage nts we re co mbined in a
0.2 ml, PCR tube and made up to a vo lume of 17.5 IlL wi th dist illed wa ter: 2 IIL o f 5X
Sequencing Buffer, 0.5 IlL of Ready Reaction Mix, 2 u l, of eit her 1.6 pmol/u l, forw ard
or reverse primer and 10-40 ng purified PCR produ ct template . A control reaction was
inclu ded wit h eac h seq uenci ng run and consis ted of2 IlL of5X Sequencing Buffer . 0.5
ilL of Read y Reaction Mix, 2 1lL of-21 M I3 Co ntro l Primer , 2 1lL of pGEM oo-3Zf( +)
template , and 13.5 u L of distilled wa ter. The tubes we re plaeed in an GcncAmp" peR
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Sys tem 9700 Thermal Cycler (Applied Biosystem s Inc., Fos ter Ci ty, CA) and PCR was
performed usin g the following profil e: 25 cyc les 01'96 "C for 10 s, 50 °C for 5 s, and 60
"C for 4 min ; and a 4 °C hold . Thc PCR produ cts were stored at 4 "C until pur ificati on,
when thcy were co mbined wi th 5 ILL o f 125 111M EDTA and 65 ILL of95% et hanol
(Com me rcial Alco hols , Brampt on, ON) . The tubes were br ie fly vo rtexe d and
centrifuged, cove red in foil an d sto red al4°C ove rnig ht. The tubes were ce ntrifuged at
3,000 x g for 30 min at RT, and the supe rnata nts we re discarde d by qu ickl y inve rting the
tubes. The tubes were centri fuged at 200 x g for 25-3 0 s, a fter which 150 ILL o f7 0'X,
et hanol was added. The tube s we re vorte xed br iefl y and centrifuged at 3,000 x g fo r 15
min. The supe rna tants were discard ed and the tub es were air-dried for 10-15 min. The
purified PCR pro ducts were resuspended in 20 ILL of m.o:" Formamidc (Applied
Biosystcms lnc., Foster City, CA) and briefly vo rtexe d and cent rifuged . The sample s
we re then loaded into a cassette and place d in a 3130 or 3730 Gene tic Analyze r (A pplied
Biosystcm s Inc., Fos te r City, CA) .
Sequence Analysis
Sequence s we re analyzed using Scqucnchcr" versio n 4 . 10. 1 (Gene Codes
Corporation). Experimental seque nces wer e aligned to the 136 reference ge nome.
downlo aded from Enscm bl Mou se Geno me Brow ser release 6 1 (NC BI m37; Febru ary
20 11; Flicek et al. 20 11; www .en sembl. or g).
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2.3 Ser um Anal ysis
Serum Collection
Whole-blood was co llected between 9:00 am and II :00 am to ensure consistency
in cycling hormone levels. Mice were decapita ted using scissors and approximately 1
mL of trunk blood was collected in a 1.5 mL microcentrifuge tube. The blood samples
were left on ice for 2 h to permit clotting, after whieh they were centrifuged at 15,000 x g
for 10 min. The clear upper serum phase was transferred in 100 ~IL aliquots to a 0.6 mL
rnicroccntrifugc tube (Fisher Scientific, Fair Lawn, NJ) and stored at -20 °C.
Enzyme-linked Immunosorb ent Assay
Seven samples from each of the following groups were assayed for serum DIIEA
levels: SWR control, SWR DHEA-treated, Line 4-T DHEA-treated ; and three samp les
from the Line 4-T contro l group. Samples were packaged in dry ice and express shipped
to the University ofYir ginia Center for Research in Reproduction Ligand Assay &
Analysis Core Laboratory where an enzyme-linked immunosorbcnt assay (ELISA) for
serum DIIEA was conducted using a DRG DIIEA ELISA Kit (ALPCO Diagnostics,
Salem, Ni l). Control samples were undiluted and DIIEA-tre ated samples were diluted
1/10 to be within the reportable assay range of 0.37 to 3.70ng/mL. Serum DIIEA levels
were assayed in duplicate when the serum volume permitted and averaged. Group
DIIEA levels were expressed as mean ± standard error of the mean. Serum Dl lEA was
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analyzed usinga Student 's unpaired t-tcst (I' < 0.( 5) using CiraphPad Prism.
2.4 Ce ne Exprcss iun Ana lyscs
Tissue Collect ion
Mice wcrc cuthanizcd by exposure toC Oz gas between J-4 wk of age for the
qualitative gene analysis and I wk post [)I lEA implantation (4 wk of age) forthe
quantitative gene analysis. The tissues were dissected using scissors and tweezers
cleaned with an Ambion" RNasc.%'lIfJ'" wipe (Applied Hiosystcms lnc., Foster City, CAl ,
and were placed in a dish of' l X Dulbcccos phosphate-buffered saline (Invitrogen,
Carlsbad, CAl . Thc tissues were blotted (Ina kim wipe, placed in a nuclease-free 2.0 nil ,
cryogenic vial (Corning Incorporated. Corn ing, NY), and flash frozen in liquid nitrogen.
The tissues were stored at- XO°c.
UNA Ext ractionfrom Mousv Ovari es
Total ribonucleic acid (RNA) was extracted from whole mouse ovaries using an
Ambion'" RNAqueous·,v-4I'CR Kit (Catalogue Number ;\1\·11914: Applied Biosystcms
lnc.. Foster City, CA) with a number of protoco! changes to optimize RNA concentration.
Pools ofat least six ovaries Ih llllthn:ci ndividualm icewere plaeed iu nuclcnsc-Ircc 1.5
ml. microccntrifugc tubes with 150 Il l. of Lysis/Binding Solution, and homogenized
using a plastic pestle cleaned with an Ambion ik) RNase.%'lIfJ'" wipe. Al SOul. aliquot of
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64%,ethanol was added to the lysate, which was mixed by pipctting, applied to a filter
column in a collect ion tube, and centrifuged at 15,000 x g for I min. A 700 pL aliqu ot of
Wash Solution #-I was added to the filt er column, followed by two aliquots of 500 p L of
Wash Solution #-2/3. The tubeswerecentrifligedat l5, 000xg fllr I min after the addition
of each reagent , foll owed by a final 30 s centrifugatio n at 15,000 x g. The flow-th rough
was discarded atier each centrifugation. The filter column was transfer red to anew
collectio n tube and aliquots 01'60 and 40 uL of Elution Solution heated to 75°C were
pipetled onto the center of thefilter, with 30 s cent rifligations at1 5,000 x g atier the
additio n of each aliquot. The eluate was combined with 10 ~I L of lOX DNasc I l3uffer
and I uL of DNase I in a nuclease-free 0.2 mL PCR tube, which was placed in a Veriti 1M
96-We ll Thermal Cycler where they were incubated for 30 min at 37 °C. Following the
incuba tion, 11.1 ~IL of DNase Inactivation Reagent was added to the tubes, which were
then incubate d at RT tor z min and centrifuged at 10,000 x g for I min. The supernatant
was transfer red to a nuclease- free 1.5 mL microcentrifuge tube, and 12.2 ~I L of5 M
Ammo nium Acetate, 2.69 u L of Linear Acry lami dc, and 343 uL of anhydrous ethanol
(Bio Basic Inc.. Markham, ON) was added. The tubes were vigoro usly inverted and
placed at -20 °C for I h, after which they were centrifuged at 15,000 x g for 15 min. The
supernata nt was removed and the RNA pellets were resuspended in 20 ~l L of Elution
Solution heated to 75 °C. The RNA samp les were stored at -80 °C until assayed for RNA
integrity.
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RNA Extractionfrom OIlier Tissues
Total RNA was extracted from liver. brain. and testes ofS WR and Line 4-T
liuc rmatc males. and GC tumour tissue from Line 4-3 recombinant subcongcnic (l C
tumour susceptible females used for phenotypic mapping. using TRlzol " Reagent
(Inv itrogen. Car lsbad. CAl. Samples were placed in a nuclease- fre e 1.5 mL
microccntrifugc tube with 400 uL ofTRlzol " Reagent and homogeni zed on ice using a
nuclease-free plastic pestle. A second aliquot of 400 uL ofT Rlzor " Reagent was added
to the tubes. and the lysate was transferred to a Oiashrcddcr" (Qiagcn lnc.. Mississauga.
ON) filt er column in a co llection tube. The Qiashrcdd cr ' " was centrifuged at 15.000 x g
for 2 min at RT. and the supernatant was transferred to a nuclease-free 1.5 mL
microccn trifugc tube and centrifuged at 15.000 x g fo r 5 min at 4 °C. The supern atant
was transferred to a nuclease-tree 1.5 mL microcc ntrifugc tube. and was incubated at RT
for 5 min. A 200 u L aliquot of' chloroform (Fisher Scien tific. Fair Lawn. N.I) was added
to the tubes. which were vigorously inverted for 15 s and incubated at RT fix 3 min. The
tubes were centrifuged at 15.000x g for 15 min at 4 °C to separate the aqueous and
organic phases. The clear upper aqueous phase was transferred in 100 u l.u liquots to a
nuclease-tree 1.5 mL mi croccntri fugc tube. A 500 u L aliquot of isopro panol (BDI I Inc..
Toronto. ON) was added to the solution. which was mixed by pipcuin g, The tubes were
centrifuged at 15.000 x g for 10 min at 4 °C to pellet the RNA. and the supernatant was
removed. The RNA pellet was resuspended with two sequential aliquots of XOO u L of
75'1..ethanol. after which the lubes were centrifuged at 15.000 x g for 5 min at 4 °C and
the superna tant was removed. The RNA pellets were resuspended in 25-50 uL of
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nuclease-ti'eewater (Applied13iosystems Inc.. Foster City. CA) dependingon the size of
the pellet. and the tubes were gently agitated to aid in solubilization of the pellet. The
RNA samples were stored at -XO°C until assayed for RNA integrity.
RNA samples from liver. brain. testes and GC tumour tissues obtained using the
TRlm r" Reagent method were purified and concentrated using an RNeasy" Minlilutc'
Cleanup Kit and RNase-Free DNase Set (Catalogue Numbers 72404 and 79254; Qiagen
Inc.. Mississauga. ON) as per the manufacturer 's standard protocol. Brietl y. 30-40 fig of
RNA was combined in a nuclease-free 1.5 mL microccntrifugc tube with 10 ul. of Buffer
ROD and 2.5 uL of DNase I stock solution. and made up to a 100 uL volume with
nucl ease-fr ee water. The solution was len to incubate tor 10 min at RT. aft er which 350
uL of Buffer RLT and 250 uL of anhydrous ethanol (Bio Basic Inc.. Markham. ON) was
added. The sample was centrifuged at 15.000 x g for IS s in a filter column in a
collection tube. The filtercolumn was placed in a new collection tube. and 500 flLof
Buffer RPE was added and the tubes were centrifu ged at 15.000 x g for 15 s. A 500 uL
aliquot of XO% ethanol (Commer cial Alcohols. Brampion. ON) was added to the tiller
column. and the tubes were centrifuged at 15.000 x gtor 2min. The filtercolumn was
transfe rred to a new collection tube. and the tubes were centrifuged at 15.000 x g 1'01'5
min withthel id ofthetilter columnopen. The filterc olumn was transferred to a
nuclease-free 1.5 ml, microccntrifugc tube. and 14 uL ofn uclease-free water was
pipetted directly onto the center of the filter membrane. The tubes were centrifuged at
15.000 x g for I min. All centrifugations were conducted at RT. The concentrated RNA
samples were stored at -XO"C.
5X
RNA Electro phoresis and Spec/roph% lllell:1'
The integ rity of a ll RNA sa mples was assessed by horizontal ele ctro pho resis
throug h a 1% aga rosc gel, Nuc lease -free water (7 u L), 2 u L ofgel load ing buffe r an d I
ul, of RNA were co mbined in a nucl ease -fre e 0.2 m l, PCR tube an d mixed by pipcu iug.
T he ge ls were comprised 01'0 .5 g ofagaro sc (Si gma-A ld ric h Inc.. SI. louis. MO ). 5 m l,
of lOX TI3E and 45 m l, of di st illcd water, T he gc ls were cast . load ed and PCR prod ucts
visua lized as perthe pro tocol for SS l.P gcnotyp ing mark ers (sec tion 2.2 . 1.3). T he ge ls
were e lectropho rese d for 30 min at 100 V. Intact RNA was indi cat ed by two dist inct
ba nds represe ntin g 2SS and ISS rR NA subunits. whereas a smear on the ge l indi ca ted
degraded RNA. RNA samples obtaincd usi ng the T R lzo l" Reagent ex trac tio n meth od
were assess ed fo r integrity bef ore and afte r puri fi cati on and co ncentrat ion .
T he R, A sa mples were assessed fix co ncentration and pur ity us ing a Nano Dro p
100 0 Spect rophoto mete r (T hermo Fis he r Scie nti fic . W ilm ington . DE). A I u l, sa mple of
RNA was ana lyzed fo r abso rbe nc y a t 260 1111. RNA sam ples obta ined using the T Rlzo l "
Rcagcnt cxtraction mcthod wcrc asscsscd for con ccn tra tion und purity bef ore and a fter
purificatio n and con cent rat ion, Idcn tica l samp lcs o f intactR NA fro m the sa me sa mple
pool tha t were foun d to be ofsim ilarconcentratio n and purit y by spec tropho tometry we re
combined an d assesse d as a si ng le sample .
eDNA Synt hesis h.l' Reve rse Transc rip tase PCR
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Complementary DNA (cDNA) was synthes ized using an Ambion"
RETRO scripl" Kit (Cata logue Number AM 1710; Appl ied Biosystems Inc.. Foster City .
CA) via a two-step reverse transcriptasc polymerase chain reaction as per the
manufacturer 's standard protocol. Briefly. a 2 fig sample of purified and concen trated
tota l RNA was combined with 2 fl L of Random Dccamer s and made up to a 12 p L
volume using nuclease-fre e water. The tubes were heated in a thermal cycler for 3 min at
75 °C, after which the fo llowing reagents were added to each tube : 2 uL of lOX Reverse
Transcriptasc Buffer. 4 ul, of dNT P mix . I uL of RNasc Inhibitor. and I uL ofMMLV-
RT. The tubes were heated in a thermal cycler for I hat 44 °C followed by a 10 min
incubation at 92 0C, aft er which they were stored at -20 °C, The cDNA samples were
assessed for concentration and purity by spectrophotometry as pcr the proto col fiJl'RNA
samples (sectio n 2.4.4) . with identical samples of similar concentration and purity
combined and assessed as a single sample. Prior to gene expressio n analyses . cDNA
sam ples were tested for integrity by amplifica tion ofa 154 bp mouse beta-actin (ll elh)
gene amplicon as per the protocol for SSLP gcnotypi ng markers (section 2.2.1). and
electro phoresed through a 1.5% agarosc ge l as per the protocol for SN P genotyping
markers (section 2.2.2.3) ( forwa rd primer: 5'-GGC TGT ATT CCC ere CAT CG-.\' :
reverse primer: 5'-CCA GTT GGT AAC AAT GCC ATG '1'-3'; Harvard Primerl3ank 11) :
667 1509aJ: Wang and Seed 2003; Spandidos cr r./. 200g; Spandidosela/. 2010:
http ://pga.mgh.harvard .edu/primcrbank).
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Printer Desig):
Primers used for cxprcssion analyscs wcrcdcsigncd using Pcrll'rim cr vcrsion
1.1.19 for Windows (Marshall 2004; http.z/pcrlprimcr.sourccforgc.nct) or retrieved from
IlarvardPrimcrBank (Appcndix B). Primcrs wcrcdcsigncdtomaximizcthcnumbcr of
uniquc transcripts rcprcscntcd, andprimcrs spanning cxon-cxonboundaricswcrc
prcfcrrcd to prcvcnt thc amplifica tionof unspliccd transcripts fi'om un-transcribcd DNA.
or contaminating DNA. All primer pairs were analyzed for gene target specifici ty using
the NCBI Primer Basic Local Alignment Search Too l (BLAST; Altschul £'111/. 1990;
www.ncbi.nlm.nih.gov/tools/primcr-blast) program. Forwa rd and reverse primerpairs
had melting temperatures within 1°C and produced nmplicons bctwccn X2 and 124 base
pairs in length. Primcr scqucnccs. thciru mplicon lengths. and the number of uniquc
transcripts amplified by each primer pair arc shown in Tablc 2.2.
2.4.1 Qualitative Gene Expression Anulysis
Qualitative expression ofprotein coding transcripts was assessed in 3-4 wk old
SWR or Line 4-T whole pooled mouse ovaries by cnd-point I'CR. Primers were
amplified from cDNA by PCR as per the protocol for SSLP gcnotyping markers (section
2.2. 1) using I p L I0 ~I M primers, and peR products were electrophoresed through a
I S Y<, agarosc gel as per the protocol for SNP gcnotyping markcrs(scct ion 2.2.2) using
40% (w/v) sucrose (Fisher Scientific , Fair Lawn, NJ) gel loading buffer, Positive
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T able 2.2 Qu alit a tive ex press ion analysi s primers. Prim er seq uences used to amplify amplicons from pro tein codin g
transcr ipts within Gct l , their am plicon sizes and the nu mber o fu niq ue transc ripts amplified , * ind icates prim ers dow nloaded
from the Harvard PrimerBank (Appendix B).
Gene Forw ard Seq uence Ifi'<s I ') Reverse Seq uence (5'--->3') .' ''( b~)~ '' Transcri pts
Gm4 36* TG CTGCT CTT AATGA TTGCCTG ACC TCC AAAAC TATCTCCACAGA 109 I II
Gm 13 178* AACCT ATGGG GT AGAT CCCTCT GAAGTATGG CTTGACTGAC CAAA 104 1/1
Gm43 8 GAAGAA CT CTAATGTGGCGG CATGG T AAGT ATCT CGCCTG 107 I II
Dhrs3* CGGGA GT CAG TCCT CAT CAC GCCCCCAG AGAAC AATCTTTC 100 SIS
Vpsl 3d TCAT ACTG CCT CAAATACAGC CAGGTC TCC TTC AATCATC TC 101 I II
Vps l 3d* CTGGAG AGGGAGCGTAACAAA ACGATTCT CGTGACACTGATG 107 3/3
,->
Tnf rsflb* GCC CAGGTTGT CTTGA CACC CAC AGC AC ATCTGAGCCTTCC 94 I II
Tnfrsf8 * ACTA CGT CAA TGAAGACGGGA TGA CA CrCA CAGATTCGAGGAG 106 I II
Gm l 3225 GT AAATA CA CCACAGGGTC TG ATGT ACAGT CT CCTCTGAGC 101 3/3
Gm l3242 GAT CAGAGGTCTCCATATGCT CTGGATCCTTT GTGAGAGTG 100 3/3
Gm132 12 ATCAA GG AAT CCACATG CAG GTT CA CT CCAGT ATTG TTTCGT 109 2/3
amplifica tion was confirmed by the presence of a single band matching the predicted
amplicon size, and the 154 bp Aclh amplicon was included with each PCR as a positive
control. Primerpairs that failed to produ ce a band in ovary cDNA were tested against
testes, livcr, and/orbrainti ssuc eDNA, asncecssary. Primerpairs that failed in all tissues
were redesig ned using the protocol above (section 2.4).
2.4 .2 Qua ntita tive Ge ne Express ion Analys is
Experimental Groupsfor Quantitative Comparison
Quantitativc real-time PCR (qPCR) was conducted to assay for differences in
mouse tumour necrosis factor receptor superfamily, member Ib (TII/i 'sj l h) messenger
RNA (mRNA) expression (Enscmbl gene 10: ENSMUSG0000002X599. transcript ID:
ENSMUST00000030336) between 4 wk ofag c whole pooled mouse ovaries in two
experimental comparisons: I) DIIEA-trcated SWR and Line 4-T, and 2) DIIEA-treated
and untreated (control) SWR (Figure 2.3). Three ovary pools were assesse d from each
group. TII/i 's/I h gene expression was normalized to thee ndogcnous housekeeping mouse
Actb gcnc in all quantitative gene expression analys es.
f) elermilla liollo/Pri merE/./iciell(I '
Prirncrcff icicncy te') was calculated as follows, using the slopco f the standard
63
4wk CAST4T
JGCT resistant
DHEA tr eatment
pooled ov aries
./ 4 w k SWR '<,
/' JGCTsuscept ible ~
DHEA t reatment
pooled ovaries
4 w kSWR
JGCTsuscept ible
Sham t reatm ent
poo led ovaries
Figure 2.3 Quant itat ive Tnf rsflb express ion anal ysis paradi gm
ql'CR was conducted to assay for di ffere nces in Tnfrsf l b mR NA ex pression betw een 4
wkofagcwho le poo lcdlllouscovaricsintwoexperilll enta lcomparisons : I)SW Ra nd
Linc4-T treated wi th DI IEA. and 2) D11EA-treated and unt reated (co ntro l) SW R. Three
ova ry pools were ass ess ed from each group.
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curve generated by plotting thrcshold cyclc ICr} versus tempJatce onccntrationforthc
Tnfrsfl b and Actb primer pairs:
E = 101- 1I s /ope l
Five '/, se rial dilut ions ofcDNA were prepared by combining approximately 1.5 pg/flL
eDNA with distilled water in a 0.6 mL microccntrifugc tube. Duplicates of each eDNA
dilut ion were pipetted into the wells ofa Micro/vmp" Optical 96-Wcll Reaction Plate
(Applied Biosystcms Inc.. Foster City. CAl with 12.5 pL of Power SYBIr" Green PCR
Master Mix (Applied Biosystcms Inc.. Foster City. CAl and 3 uL of O.5X3 pM forward
and reverse primers. Each reaction plate included two non-template control reactions per
primerpair/eD NA sample as a negative control. The reaction plates were covered with a
Micro/vmp" Optical Adhesive Film (Applied Biosystcms Inc" Foster City. CAl and
centri fuged at 670 x g for 2 min, after which they were placed in an ABI PRISM"" 7000
Sequence Dcteetion System (Applied Biosystcms Inc.. Foster City. CAl where qPCR was
performcdusing thetl)llowingpro lilc: 95 °Cf l)r 10 min; 40 cycles of95 "C for 15 s and
60 °C fo r I min. Data was analyzed using ABI PRISM'" 7000 Sequence Detection
System So ftw are version 1,2.3 (Applied Biosystcms Inc.• Foste r City. CAl. A primer
cfficicncy bctwccn Sfi'zs aud 100% was considered to be acceptable.
Qnantitativc Real-time PCR
Based on the standard curve generated dur ing primer efficiency testing, eDNA
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samples used for thc qPCR analysis were diluted to a 1/ 16 conccntration by combining
2.69 flL of approximately 1.5 flg/pL cDNA with 40.3 1 pL of distillcd wat er in a O.6 mL
microccntrifugc tube. The dilutions were briefly voricxc d and centrifug ed. and a 6.5 u l,
aliquot ofeach cDNA dilution was co mb ined with 12.5 u l, of Power SYI3R" G ree n PCR
Master Mix and 3 ul, ofO.5!'3 flM forward and reverse primers in the wells ofa
Micro/vmp" Optical 96-Wcll Reaction Plate. Each reaction was assayed in triplicate in
three independent experiments, qPCR was conducted as pCI'the protocol for primer
efficiency determination.
Statistical Analysis
Triplicate Ct measurements were averaged for each gene: outliers were excluded.
in which case mean s were determined using two repli cate val ues , Fold changes in ge ne
expressio n were calcu lated according to Pfaffl (200 1) using the equation:
whcrcErar!'rris thcp rimcrcfficicncyofthc Tllji'sjlh primcr pairand /:'rrris thc primcr
cffic icncy oft hcActh primcr pair. l-old clumgcs calculutcd from each reaction plate were
expressed as mean ± standard error ofthe mean, relative to Line 4-T (comparison I) or
DIIEA-trcalc d SWR (comparison 2) sa mples. and were analyzed by two-way analysis of
variance with Tukcys post test using GraphPad Prism.
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2.5 Candidate Ge ne Sequencing
The Tnfrsfl b gene was amplified from genomic (cxon I and 10) or
complimcntary tcxons 2-9) DNA usingninc primer pairs with ovcrlapping amplicons.
Primcrscqucnccs and thcir amplicon lengths and arc shown in Tablc2 .3. Primers were
amplified by PCR and products were electrophoresed. purified. and sequenced as per the
protocol lor SNP gcnotyping markers (section 2.2.2). Tnfrsf l b was sequenced from four
individuals from both SWR and Linc 4-T. and all primer pairs except for those
amplifying cxon IO-Dwere also sequenced from thrcc B6 individuals. A c.114XT>C
mutation in TII/i"s/I h cDNA found in SWR resulting in an amino acid change was
amplified from genomic DNA (forward primer: 5'- AGC AGC ACC TGT TGA CCA -3':
reverse primer: 5'- GCC AGC TAT CTG TCC AGA GC -3' ) as per the protocol abovc.
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Tab le 2.3 Tnfrsfl b seq uenci ng primers. Prim er sequences used to amplify overlapping exon segments oft he Tnfrsflb gene.
their nucleotide range s and exo ns amplified, amplic on length s, and type oftcmplate input required . Nuc leotide ranges are
rela tive to Tnfrsfl b cDNA bp I. cDNA: comp lementary DNA ; gDNA: genomic DNA.
Exons Nucleotide Amp licon Temp late
Amplified Ranges
Forward Sequence (5' ----> 3') Reverse Sequence (5' ---->3')
(bp) Inpu t
Exon I -39- 190 Cl' GGl'C l' GCCC l' AGCl'CCl' CAGl' AGCl'GGAAl'GGGCACl' 249 gDNA
Exons 2-5 100-641 Gl'C TTCG AACl' GC AGC TGl' G Cl' GCAl' Cl'Gl'GCl'l'GCA TTl' 57 1 cDNA
Exons 6-9 575-1226 GGACGTl'C l'C l' GAC ACC ACA GCl' GCl' ACAGACGTTCA CGA 671 cD NA
cc
Exon 10 1135-1 902 l'Gl'Cl' CCAA GAl'CCCCAGA C GGGCl'l'GGAGAGGGl'ACl'TC 787 gDNA
Exon 10 1867-2556 CACAGAGGCCC l' l'C AGGl' l' A TAGGCTCCl'Cl'GCCAAGTTC 709 gDNA
Exon 10 24 71- 32 17 GGAAGGAAAGGGTTCAGGAG l'GAAGGAGGGAGATTCTGGA 766 gDNA
Exon 10 3165 - 3354 GCAGGGAA CAAl'Tl'GAGl'GC Al'GAGAGCCCl'GCCT CAGTA 209 gDNA
Exon 10 3226 - 3429 TCCCTCCTT CAGl' GTGl'Gl'G AA CCTGAGCACTCCATAGG C 223 gDNA
Exon 10 33 79 - +43 CCC AGAGCl' TGC AC Al' l' l' l'C GAl'GCAGCCAGACTGGGl'AT 500 gDNA
3. Results
3.1 Phenotypi c .\ \:Ipping of Gel I
3.1.\ Developmenr uft he Linc4-3 Rccumlunant Subc onge n lc Line s
Six informative SWR.SJL-X.Ci\ST -4 recombinant subcongcnic lines (hereafter
refe rred to as Lines 4- 11 through 4- 16) with unique recombinations of thc Gelrl 'w and
Gel lc allelcs across thc Gel l iocus wcrcs ucccssfully dcrivcd from Linc4- 3 and tested
forG t, tumour incidence. Females homozygous fort he ncw congcnic portions around
Gct l were exposed to DIIEi\ at puberty to increase trait pcnctrancc with a desired cohort
of n = 50 females per line. with an g wk endpoint for GC tumour assessment. Thc
haplotype patterns ofSWR. Linc 4-3. and Lines 4- 11 through 4-16 for annotated (l J4Mil )
and in-house designed (D4sjh) polymorphic DNi\ markers int hc Get I interval arc shown
in Figurc3 .1. ( jC tumour frequencies, indicatcdasthcnumbcroftcmalcswithGC
tumours versus the total number of females examined. arc reported below the locus
haplotype for each linc.
Thc Gt. tumourp henotype observed in Lincs4-l lthrough4- 16 was similar to
thalrcportcdinthclitcratu rc. i.c.lincsth aldidn otdcvclop GC lumoursw crccomplctcly
rcsistant toG C initiation up ro x wk. und thosc Iincs that wcrc Gt. tumoursu sceptible
dcvclopcdJ argcuniJ atcralorbilalcraltumourswithinXwkat thccxpcctcdli'cqucncyof
approximately 20'Yo. Females from Lines 4- 11. 4-13. and 4- 15 had a significantly higher
GC tumour incidence (27.3%1. IX.4%. and 17.6%,. respectively) than Line 4-3. 4- 12. 4- 14.
69
SUbcongen ic lin es
DNA marke r Chr 4 position (Mb)
• CAST l ...D SWR D4Mit13 0 0 i 0 0 i 142.09
D4Mit126 0 0 • 0 0 . 142.15D4sjh19 0 0 • 0 0 • 142.69D4Mit160 D 0 • • • • 144.04D4sjh10 D 0 • • • • 144.21D4Mit232 0 0 0 • 0 . 144.64
Gct1
D4Mit233 0 0 0 • 0 • 144.80
Interval
D4Mit285 0 0 0 0 0 0 146.81
(2.6 Mb)
D4Mit206 D 0 0 0 0 0 147.25
Nppb D • 0 0 0 0 147.36D4sjh11 D • 0 0 0 0 147.54D4sjh12 0 • 0 0 0 0 147.64D4sjh13 0 • 0 0 0 0 148.09D4Mit129 0 • 0 0 0 0 0 148.30D4Mit49 0 • 0 0 0 0 0 148.57
# females with GC tumours 1209 0 9 0
# females examined 44 50 49 55 Sf 51
GC tumourfrequ ncy (%) 27.3 018.4 017.60
Figure 3. 1 Chr 4 hap lotyp es of SW R, Liue 4-3, and the SW R.S.JL-X.CAST -4
recombina nt subco nge nic mouse lines at Get !
Females from SWR and the subcongcnic lines 4-11. 4-13. and 4-15 have significantly
incrcascdGC tumour incidcncc than Linc4 -3 and lincs 4- 12.4-14. and4 -16(!' <
0.(0 26). The GC tumour susceptible strains share common regions of SWR genetic
background between markers D4.1'ih lO and D4lvli1285. fora minimal genetic segment
containing Get I ofapproximately 2.6 Mb. +: GC tumour susceptible: -: CiC tumour
resistant: black boxes: CAST alleles: blue boxes: SWR alleles: yellow rectangle: the Gct l
interval.
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and 4- 16 females, which were completely GC tumour resistant (0%.; P < 0.(026). GC
tumour frequencies between the three susceptible lines were not statistically different.
This indicates that the Line 4-3 recombinant subcongcnic Lines 4- 11, 4- 13, and 4- 15
carry the Celtl'w allele, whereas Lines 4- 12, 4- 14, and 4- 16 retain the c.o" tumour
resistance allele. The phenotype-driven mapping process indicated that Cel IsII'resides in
the region betwee n D4s ;h 10 and D4Mi1285, an approximately 2.6 Mb interval.
:U .2 Relining th c Gc nctic Bound arics of Get !
Subcongcnic Lines 4- 13 and 4- 15 defin ed the proximal boundary for Cel l ,
whereas Lines 4- 14 and 4- 16 defined the distal boundary (Figure 3. 1). To achieve greater
resolution of the Cel l interval and exclude potentia l candidate genes, it was desirab le to
achieve greater mapping resolution at these boundar ies.
A lack of annotated, informative SSL P markers or predicted SSLPs around which
primers could be designed within the 2.6 Mb interval necessitated the identification of
other polymorphisms betwee n the CAST genome and the as yet un-scqucnccd strain
SWR. SNP genotyping markers were pursued for several genes: Natriuretic pep tide typ e
B (Npph ; Appendix A) , Tnfrsfl b, and Dehydrogenase/redu ctase (SDR./ llllli/r) mcmhcr 3
(Dhrs.1). SNP-bascd genotyping markers were designed to amplify a single product with
one or more predicted single bp differences between SWR and CAST, or were designed
around annotated SNPs for which the CAST allele is known and different fi'OI11 all other
strains (Tab le 3. 1).
Eleven SNPs were identified within the three markers designed to amplify
7 1
Ta ble 3.1 SS L P and S~ P ge noty p ing marker s. Primer seq uences and locat ion on Chr 4 are sho wn (Ense mbl release 6 1. NC BI
m37) . Entries in bol d we re empiri cally deri ved in-house . C: CAS T; nfa : no t applicab le; S: SW R
Forward Sequence (5'-.3') Rcvcrsc Scq ucncc tS's-sJ') Amplified Region of
Chr 4 (bp)
GCTGGT AGCTGG CTTTT CTC CAG ATGTT CCTACTG CTTGG 142,094,205- 142,094.293 SSLP
TGCAC TTTTGAGATTGCCAG GTCTTTCCC TCTCCC TCCC 142.152.658-142 .152,805 SSL P
D4sj h/9 GTGGGGAG CATGTCCTTAAA TGGG AGTGTGT AGCAGAGGA 142.633.3 17- 142.633.5 44 SSL P C > S
D4,I/il/60 ACTATGC TAAA CCAACAATCTCCC CCGAGAAACCTAATCTTGATGA 144.040.0 10-144 .040 .205 SSL P C > S
D4sjh/1I GCAGAAA TGGCACAG GAGAT CCC ACATTTGAAA CCAC CTC 144.208.822- 144.209.061 SSL P
D/lr.d AC \ TCT GGlTGT GGGAGA CGGA AA AG CC \G ,\G ,\TGC rT ,\ GGTC TG T GT 144,5 17,967- 144,5 18,288 S:\' I'
D4.\jh 9 GGA CTGG CTCTGAG GAACAA GCC AAGCAGCTTCC TCTTAG 144.635.848- 144.636.084 SSLI' C < S
D4A1il232 GCGT CACCACACTGCTCTT ACTCAGA GTCCCCTG GCC 144.647.559-1 44.647.676 SSL P C > S
0 4,\/il 233 TGGT CATGTGTG TCCATGC ACTTCATGTAGC CAGGTGGG 144.8 14.847-1 44,8 15.021 SSLP
1'-' Tllln jlb CAC ,\G ,\G GCC CTT C \GGTTA T ,\ GGCT CCTCTG CCAAGTTC 144,804,628- 144,805,298
D4kll s/ TTTA CAGA GAG,\ ,\ ACCCGGGCACT ACAC CC,\ ,\G 1TGC GC \ ,\ GAATC T G 145,720,468-1 45,720,843
CTTTAGGT AGAA CTTCTTCCGTTTT GTGGCAGTGAAACTTATTCAACC 146,815,380--146,815.479
TGAAGG CCTGAGTTAATACCTAGC TCATCAACTAAGTGACAAGGAAGG 147.251.451-14 7.251.598 SSLI' C <S
Nppb GAAGA CACCAGT GCACAAGC AATCCCCCATCCTTCCATAG 147.360.003- 147.360,359
Dusjh l l CCACCAGGTCTGGATAG CAT GCC AGGAAGGCTAGCATAAA 147,540.887-14 7,541.1 18
04.\j h/2 TTTGGAGA CCAAAGA TGAGA CA CTTTTCTGGCC TCTGACCTG 147,643.33 1- 147.643.56 1
04 sjh / 3 TCTGGTTTCTATGCGTGTG C CGGGATCCATATGGTAGTGG 148,093.433- 148,093.658 SSL P C >S
04 .11;1/29 GTAAA TACACAACCATAGAGACCTG C TGCCTG CCTACTTGTGTTTG 148,297,268- 148,297 ,396 SSLP C > S
TTGC CTAGCATACCTGCATG GCTGGGTTTGTGGCTCAG 148,572,905-14 8,573,054 SSLP C > S
segments in and around candidat e genes in SWR and Line 4-T . which were later assessed
in individuals from the informative Linc4-3 rccombin ant subcongcnic lines, These
included three SNPs within Nppb, six SNPs within Tnfrsfl b, and two SNl' s slightly
upstream o fDll rs3 (Table 3.2). All three SNPs amplified by thc Npph marker and two of
thc SNPs ampl ificdbythc7i1fi-sjl hmarkcrwcrcnovcl ; allothcrswcrc annot atcdin
dbSNP13uild 132. Allhou gh Npph scqucncingwasinformativcf()rmappingpurposcs. it
was excluded as a candidate gene based on the haplotype pattern s of l.incs 4- 11. 4-14. 4-
16. Tnfrsf l h and Dllrs3 were located with in the 2.6 Mb Get I interval and were
sequenced formappingand/orcand idacy as GCtumour susccptib ility gcncs. The
identification of polymorph isms between CAST and SWR alleles with in Tnfrsf l b and 62
and 145 bp downstream of thc 3' untranslatcd region (UTR) of Dllrs3 allowed for
gcnotypcassignmcnto f thcsubcongcnic lincsas wcllas inclusion oft hese genes within
thc candidatc Gel1 interval.
Annotated SN P gcnotyping markcrs from dbSNI' Build 132wcrccmpirically
tested for polymorphic base changes between CAST and SWR; only one marker, D4knsl .
amplified a single product that was polymorphi c between CAST and SWR and could be
reliably assessed in all rccombinant subcongcnic lines. Twenty previo usly unreported
SN Pswcrc idcntificd within thc376 bp D4kns l arnplicon dcsigncd to amplify
rs27631336. a G-+ T substitution at bp position 232 of thc amplicon at genomic position
145.720.699thatlics with in the pscudogcnc G111 13241 (Tablc 3.3). Thc expected
rs27631336 bp substitution was not present in Line 4-T or recombinant subcongcnic mice
inferred to be carrying the CAST allele, In addition to thc 20 novel SNPs. thc annotated
SN Prs49752369wasa iso identified in the D4kllSI arnplicon. Two SNPsa t bppositions
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Table 3.2 A n no tatcd a nd novel SNl's idc ntilicd w ithi n gc nc ca nd idatcs . Gen es. ge nic
and ge no mic locat ions. a lle les and dbSNP ID num bers. ifapplica ble, arc show n. (+ ):
forward stra nd; (-): reve rse stran d; + : prior to ge ne eDNA bp I
Ge nic
Assoc ia ted Gene Ge nomic CAST SW R
Locati on dh SNI' ID
(st ran d) Location (bp ) A lle le All ele
(bp)
Dhr s3 (+) +62 144.5I R. 174 rs32447066
+ 145 144.5I R.257 rs3301 31 20
Tnti's fl b(-) 23R7 I44 .R04.79 7 nove l
234R 144.R04.R36 rs32429059
2325 144.R04.R59 rs27 627703
2050 144.R05.134 novel
1994 144.R05.190 rs4720 370 5
196 6 144.R05,2I R rs27 62770 1
Nppb( +) 149 147,360.045 novel
161 147.360.056 novel
26 7 147,360.163 rs32950646
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Table 3.3 Anno tate d and novel S N Ps ide nt ifie d w ithin t he fragmcnt amp lifie d by
D4kllsJ . S NI' locations. alle les and dbSNI' ID numbers, if applicab le arc shown. *
indica tes SN l's used for gcnotyping
Position in Amplicon Geno mic 136 CAST S W R db S NP ID(bp) Position (bp) Alle le A lle le All ele
39 145,720 ,50 6 novel
5R 145,720 ,525 novel
74 145.720 .54 1 nove l
77 14 5.720 .544 novel
RR 14 5.720 .555 novel
99 145. 720. 566 novel
109 145,720,576 novel
117 145,720,5R4 rs49752369
14R 145,720,61 5 novel
174 145.720,64 1 novel
IR5 145.720.652 novel
IR6 145.720 .653 novel
2 1R 14 5.720.6R5 novel
22R* 14 5.720 ,695 nove l
264* 14 5.720 .731 novel
2RR 14 5.720.755 novel
290 145,720. 757 novel
294 145,720.761 novel
30 1 145,720 ,76R novel
304 145,720,77 1 novel
330 145,720,797 novel
75
22R and 264 of the amplicon were polymorphic between CAST and SWR and were used
forgcnotypin g. The additiono f D4kl1.\,/ to the Chr4 haplotype map resulted in a refined
Gc/ /intervalo f l .5 1 Mb (Figure 3.2).
3.2 Th e Refin ed Get/ Inte rva l
3.2 . 1. / llsilico [)ata
The 1.51 Mb Gc/ / interval contains 43 unique genetic determinants. including 15
protein coding genes. fo urp rocessed transcripts. four non-coding RNA genes. and 20
pscud ogcn cs (Figure 3.3; Enscmbl Mouse Genome Browser release 61; NCBI m37
February 201I). The major ity of the genetic entities in Gc/ / are locatedat thedi sial end
of the interval, which is particularly pscudogcnc-rich and contains repetit ive genetic
clements. Table 3.4 summarizes the featur es of the 23 genes which we hypothesize will
include a genetic determinant that is causative for GC tumourigcncsis.
Only four of the 15 protein coding genes - DhrsI , lips / 3D . Tnfrsfl b, and Tnfi 'sfS
have been described in the literature with defined or speculated rolcs in human or
mouse. Tissue specific gene expression levels have been examined for these fourg enes
by m icro arra y in both species; Table 3.5 shows the rc lativc cxprcss ion data lorthese
genes between the male and female mouse gonads. based on the Gene Expression Atlas
initiative (Su et al. 2( 04) accessed through the l3ioGI'S web portal (Wu e/ a/ . 2009;
www.biogps.gnf.org). All four genes show detectable expression in the testis and ovary
in both species; however. Dllr,d and Tnfrsfl b show greater abundance in the female
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GC tumour frequncy (%)
# females with GCt umours
# femalesexammed
Chr 4 posit ion (Mb)
• CAST
D SWR
DNA marker
~
D4Mit13 0
D4Mit126 D
D4sjh19 D
D4Mit160 D
D4sj h10 D
Dhrs3 D
D4Mit232 D
D4Mit233 D
Tnfrsf1b D
D4kns1 D
D4Mit28S D
D4Mit206 D
Nppb D
D4sj /J11D
D4sj/J12 D
D4sjh1 3 D
D4Mit129 D
D4Mit49 D
Subc ong enic lin es
D II 0 0 II 142.09
D • D D • 142.15
o • 0 D • 142.69
D •••• 144.04
D •••• 144.21
D D . D • 144.48
D D . D • 144.65
D D . D • 144.80
D D . D • 144.81
D D D D D 145.72
D D D D D 146.81
D D D D D 147.25
• D D D D 147.36
• D D D D 147.54
• D D D D 147.64
• D D D D 148.09
• D D D D D 148.30
• D D D D D 148.57
120 90 90
44 50 49 -s5 51 Sf
27.3 0 18.4 0 17.6 0
Gct1
interval
(1.51 Mb)
Figure 3.2 C hr 4 hapl otyp es of SW R, Line 4-3 , a nd th e SW R.S.JL-X.CAST-4
recnmbina nt subcunge nic mou se lines at th e refin ed Get I int er val.
The GC tumour susceptible strains share common region s ofSW R genetic back ground
between ma rkers IJ4.~ihl() and IJ4kllsl . for a minimal genetic segment co ntai ning Get I of
approxi mately 1.51 Mb. + : GC tum ou r susceptible: -: GC tum our resistant : black boxe s:
Ci\ST alleles: blue boxes: SW R allele s: yellow rectan gle : the Get I inter va l.
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Ta ble 3.4 Summary of th e genetic determinants within the 1.51 M b Gctl interval. ncRJ'IA : no n-coding RN A ; N D : no t
determ ined ; NA : non e av ailab le ; + : for w ard ; - : reverse
Ge ne De scripti on ........ ....... L...""" '"U ~ I '-' I I '-'I I St rand Ge ne typ eO nto logy Chr 4 (bp) Tr an script s
GII/I3I 77 pred icted ge ne 131 77 ND 144,203,6 10 + prot ein codi ng 1
GII/436 pred icted gene 436 ND 144 ,259,840 prot ein coding I
Gm l 3178 pred icted ge ne 131 78 ND 144,293,094 protein co ding 1
UI.I 25 U 1 splieeosoma l RNA ND 144,355 ,530 small nue lea r ne RNA 1
GII/438 predi cted gene 438 ND 144,367,10 7 prot ein co di ng 1
Dhrs3 deh ydrogen ase/redu ctase (S DR ox ido reduct- 144,4 82,730 + prot ein co dingfami ly) memb er 3 ase ac tivity
Vps / 3d vacuo lar prot ein sort ing 13D N D 144 ,562 ,526 prot ein coding(yeas t)
VpsI3d vacuolar protein sor ting 13 D ND 144,562,529 protein co ding 10(yeas t)
~ Tnfrs f l b tum our necro sis factor recept or TNF recept or 144,803,366 protein co ding
superfam ily member l b
Tllfr sfd tum our necrosis factor recepto r TNFree ept or 144,85 7,040 protein co ding
supe rfam ily memb er 8
GII/13227 pre dicte d gene 13227 ND 145,000 ,14 8 + proc essed tran script
V1I/1I2r-psI4 vome ro nas al 2, rece ptor, N D 145,054 ,10 7 + proce ssed tran scriptpseud ogenel4
GII/I3225 pred icted ge ne 13225 N O 145,100 ,662 + pro tein co ding
GII/I3 242 pred icted gen e 13242 N O 145,104 ,787 + prot ein co ding
GII/I32I2 predi cted ge ne 13212 N D 145,175,069 + prot ein co ding
AL627304. I NA N D 145,191 ,866 lon gncR NA
GII/I3236 pred icted gen e 1323 6 N D 145,352 ,832 + proc essed tran scr ipt
AL929465 .I NA ND 145,454 ,975 + mi cro RNA
GII/I3235 pre dicte d gene 13235 ND 145.4 58,697 + protein cod ing
26I0036A22Ri k RIK EN cDNA 26IOO36A22 ND 145.439,879 prot ein codin g
1700095A2IRik RIK EN cDNA 1700095A2I ND 145,65 1,166 processed tran scrip t
GII/I324 7 predicted ge ne 1324 7 ND 145 ,65 8,6 47 protein co ding
AL62 7077.I NA NO 145,686,2 75 lonu nck NA
T a b le 3.5 Relative ge ne expre ssion in the mou se gonad. Expression leve ls were
determ ined by miero array (Sue et (II. 2004) and we re acce sse d through the BioGI' S web
portal (Wu ct (II. 2009) . Dhrs3 and TII/i4Jh arc highl y ex pressed in the mouse ova ry
compare d to tes tis.
Relati ve Express ion
Gene Ovary Te stis
(ovary/te st is )
Dhrs3 969 .90 40 .67 23.X5
Vps /3d 5.97 4 .60 1.29
TII/i4Jh 112.62 13. 11 X.59
TII/i's/8 4.36 4.49 0.97
XO
versus male gonad in mice.
3.2.2 Q ua lita tive Ge ne Express ion Analysis
To empirically determine the expression of the Cel l gene candidates in the young
ovary of tumour susceptible and tumour resistant mice. the design of gene-specific
primers was attempted to capture unique amplicons representing as many transcripts as
possiblc.
Of the 23 entities, only II were success fully amplified by end-point PCk . Three
genes at the distal end of Ce l l were not pursued as their repetitive sequences prevented
their specific amplifi cation. C1II13177 is interrupted by the SS L/' marker IJ4sjh lO at the
proximal boundary of the Ce l l interval. and therefore was given low priority and was not
assessed. Furthermore. the four processed transcripts and four non-coding R A genes
were assigned low priority fix assessment. Although it is recognized that non-coding
R A genes can have a large impact on gene expression and disease susceptibility. they
were given a lower priority for analysis until the protein coding genes were defini tively
excluded fix shared identity with Cel l .
Primers were initia lly tested for the amplifi cation of a single band in SWR testis
cDNA. Those primer pairs that failed were tested in liver and brain cDNA as necessary
to determine if the primer pairs were functional. Primer pairs that failed in all tissues
were redesigned. whereas those that were successful in amplifying a single ampli con of
the desired length were tested in two pools each of ovary cDNA from 4 wk old Line 4-T
XI
and SWR mice. As shown in Table 3.6, all II of the genes that were assessed showed
positive expression in testes and the four ovary cD A pools after 39 cycles of peR .
Based on qualitative expression analysis, there was no reason to exclude these gencs as
potential candidates for shared identity with Cel l .
Qualitative assessment of the Ce l l gene transcripts served as a confi rmation of
primer specifi city prior to quantitative analysis by qPCR. In addition to the testes, Line
4-1', and SWR ovary poo ls, the Tnfrsf l h protein coding transcript was found to be
expressed in SWR liver, brain, and GC tumour tissue. Based on its biological role as a
mediator ofTNFfl function in the mouse ovary, Tnfrsfl h was prioritized as a candidate
for Cel l identity and therefore for subsequent quantitative and sequence analyscs.
3.2.3 Quantitative Gene Ex pres sion A nalys is
The quantitativ e analysis paradigm was dependent upon I wk ofDHEA
stimulation from subcutaneous capsules. As this had not been previously measured in
SWR mice, and to ensure that the capsules were having the desired effect on circulating
DIIEA levels, serum DHEA was measured by ELISA. As shown in Table 3.7, there was
no significant differ ence between serum DHEA levels in SW R ((1.5 1 ± 2.43 ng/mL) and
Line 4-1' (30.93 ± 37.59 ng/m L) mice afte r I wk of DHEA treatment, although the
DIIEA-treated Line 4-1' group showed a high degree of variability in serum DHEA
levels. Serum DHEA levels in all seven samples in the SWR contro l group were less
than 0.37 ng/mL and therefore below the reportable range of the assay. The fourth group
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Ta ble 3.6 Q ua lita tive exp ression of the Get ! transcripts within th e 1.51 I\Ih inte rva l.
ND: not determined; ./ : positive expression
Gene Gene Type
Qualitative Transcript Expression
Testes CAST Ovary SWR Ovary
Gm 1317 7 known protein coding ND
Gm436 known protein coding ./
Gm 13 / 78 known protein coding
U / . /25 novel small nuclear RNA ND ND
Gm438 known protein coding ./
IJ!Trs3 known protein coding ./
Vps /3 d known protein coding ./
Vps /3d known protein coding ./
Tnfrsfl h known protein coding
TII/i·s/S known protein coding
Gm /32 27 novel processed transcript ND
Vninlr-ps t » known processed transcript ND ND ND
Gm /3225 known protein coding ./ ./
Gm /3242 known protein coding
Gm /3212 known protein coding
A L62 7304 . / known long non-coding RNA ND
Gm /3236 novel processed transcript ND ND ND
A L929465. / novel micro RNA ND ID
Gm /3235 known protein coding NO ND
2610036A22 Rik known protein coding NO ND ND
/ 700()95A2/Rik novel processed transcript ND ND ND
Gm /324 7 known protein coding ND ND ND
AL62707 7. / known long non-coding R A NO
X3
Ta b le 3.7 Se r um ()!I EA levels in SWR and Lin e 4-'1'mice treated with D!l Et\ or
em pt y ca ps ules, Ser ums we re taken I w k followi ng ca ps ule implantation.
SW R Line4-T
DI-IEA Caps ule 0.5 1 ± 2.43 ng/m L 30.93 ± 37.59 ng/mL
Em pty Caps ule
(n =6)
< O.37 ng/m L
(n = 7)
X4
(n = 7)
(Line 4-1' co ntro l. n = 3). whic h was not incorporated into the qua ntita tive gcnc
ex pressio n ana lysis . co uld not be co m pared , as two values were outside ei ther end of thc
assa y' s repo rtable range, The only sample from th is grou p wi th a serum DH EA leve l that
fell wit hin the rep ortable range of thc assay was 1.446 ng/m L.
Tnfrsf l b mR NA ex press ion was co mpa red between ova ry pools from DH EA-
treated S W R and Linc 4-T mice . As show n in Figure 3.4A. no s ignifica nt differen ce in
Tnfrs] ]h mR NA ex press ion wa s dete cted over thr ee repea ted exp erim ent s com paring
tripl icat es o f three se ts o f ova ry poo ls . Figur e 3.4 13shows thc co mpa riso n o f Tnfrs]! b
mR NA ex press io n between ovary pool s from DH EA-treat ed SW R and SW R co ntro l
mi ce wh o rece ived an em pty ca psule. Aga in, no significa nt differe nce in Tnfrsfl b
mR NA ex pres sion was detec ted over thr cc repeate d ex per ime nts co mpa ring trip licate s of
three sets of ovar y pools.
3.2.4 TJ~lrsflh Seq ue nc ing
The Tnfrsfl h cDNA wa s sequence d fro m SW R. Line 4-1' , an d 136micc.
Nuc lco tidcand amino aci d seque nce a lignme nts forthc three seque nced stra ins arc
show n in Appe ndix C and Figur e 3.5, resp ecti vel y. As sho wn in Ta ble 3.X, 12 SN l's and
two dinu cleotide de leti ons were identified in SW R co mpared to Line 4-1' and the
pu bli sh ed and/or seque nce d 136 re ference . All 14 po lym orph ism s we re found in cxo ns 9
and 10. w hich spa n the di stal co d ing and 3' UT R reg ions of thc Tnfrsf l h cDNA . T he 12
S I's were base pair substitutions, five of whic h were in thc cod ing regio n and result ed in
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Fi:,:ure 3.4 Fo ld change in Tnfrsfl b mR NA re lat ive to Acth
No signifi cant diff erence in Tn frsf l b mR NA ex pression was detected over three rep eat ed
experimen ts co m pa ring tripli cates of A) DII EA-tr eated Line 4-T ova ries relative to
DI-IEA-trcated SW R ova rie s. or B) DI-IEA-treatcd SW R ovar ies re lative to contro l-
treat ed S W R ovaries ,
R6
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Figure 3.5 Alignment of the S\V R, Line 4-'1', a nd B6 Tnfr sfl b amino acid sequences
T he sing le ami no acid change in S W R compa red to Line 4-T and 136(p .P hc3 60 Ser) is
highl ight ed . ( *) identity; ( :) conse rva tive cha nge ; ( ) radi ca l chang e.
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Table 3.8 Nucleotide changes in SW R Tnfrsflb eD NA versus B6 and Line 4-'1'.
Nucleotide ranges arc relative to Trf rsf ]b cDNA bp I
Ge ne Nucleo tide
l3ase(s ) Amino
Polym orph ism
Exo n Changed Acid db SNP ID
Region Number Type
or Dele ted Su bs tit ution
Cod ing 1035 Substit utio n C-> T No ne rs27627669
Coding !O89 Substit ution C->T No ne rs510 45832
Coding 1148 Substit ution T-> C F-> S rs27 627 670
Co ding 1161 Subs ti tution T-> C None rs27 627 67I
10 Coding 1431 Subst itu tion G->A None rs27627694
10 3' UT R 1994 Substitut ion G->A rs4720 3705
10 3' UT R 2325 Subs titution C-> T rs27 627703
10 3' UT R 23 48 Subs titut ion G->A rs324 290 59
10 3' UT R 28 02 Substit ution C->T rs4 895637I
10 3' UT R 2X03 Subst itutio n T->G rs4 723 2340
10 3' UT R 3094 Substitution C->T rs48 07055 9
10 3' UT R 3099 Substitutio n C-> T rs480 1102()
10 3' UT R 327 9-32 80 Dele tion CC No vel
10 3'UTR 3288 -328 9 Deletion CA No ve l
foursil ent mutations and a single missense mutation, phenylalanine to serine at amino
acid 360 (p.Phc360Scr). Originallyid cnliticdin cDNA, thcp'phc360Scrvariant was
confi rmed in genomic DNA by peR and sequencing, All 12 SNPs identified in the SWR
Tnfrsf l h cDNA sequence, including that which resulted in p.Phc360Scr, arc known
variants in othermo use strains annotated indb SNP Build 132, andthcrc!i.)rcn otuniquc
to the SWR strain. The two dinucleotide deletions in thc SWR Tnjrsf] b cDNA were
present in the 3' UTR arc novel. although this region is conse rved only betw een mice and
human with low sequence identity.
4. Discussion
O\'('/Tiell'
GC tumours oft he SCST class can aff ect women at either end ofthe reproductive
spectrum. and bused on age ofonset and histology. arc divided into adult und juvcnilc
subtypes. Despite the associa tion between FOXL2 and adult GC tumours in humans. as
wcllas thc obscrvation that thccnginccrcda ltcration ofa numbcI'of crit ical genes results
in exceptionally high frequency SCST phenotypes in mice, no genes conferring innate
susccptibility to juvcnilc-onsct(,C tumours in humans ormice have been identified. GC
tumourigcncsis int hcS WR mouscrccapitulatcsi nhcrcnts usccptibility tocariy-onsctGC
tumours at a frcqucncy otz l'zc genetic investigation of this trait has identified Gel / on
distaimousc Chr4 asa fundamental locus forGCtu mourin itiation.
The Gel / locus shows the strongest and most consistent association with the GC
tumour phenotype for this polygenic trait. which is characteri zed by a restricted window
ofsusceptibility and endocri nological sensitivity that coincides with the mouse 's pubertal
transition. Thc usc ofandrogcns as u method to increase trait pcnctruncc has facilitated
the genetic mappingofGel / . and reinforces the extent ofsteroid honnonc influence upon
thc mcchanismofGC tumour initiation in the complex biology ofth cm ammalian ovary .
The objec tive ofth is thesis was to positionally clone the Gel / locus. using a subcongcnic
mappings tratcgy to produccashortlisto fca ndidatcgcncsfi.lr prioritizcd qualitativc.
quantitativcand scqucncc-bascd asscssmcnts. jo rcsolvc thc gcnctic dctcrminantl hat
sharcs idcntity withGel / .
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4.\ Get J Rcs idesWithina 1.5 \ i\lb lntcrva l
The phenotypic mapping strategy using Line 4-3 as a start ing strain for the
generation of recombinaIII subcongcnic lines successfully refined the Gel! interval from
6.4R Mb to 1.51 Mh, a region between the markers 1J4.IN!Oand 1J4km! . This region of
mouse Chr4 contains a total 01'23 protein coding genes. processed transcripts. and non-
coding RNA genes. as well as 20 annotated pseudogenes. The refinement of Gel ! was
aided by the empirical identification of novel SSLP- and SNI'-based genotyping DNA
markers that arc polymorphic between the SWR and CAST strains. as the published DNA
marker resources had been exhausted. The identification of polymorph isms within Gel!
gene candidates was essential for mapp ing purposes and the exclusion of genes from the
interval. It should be noted that until Gel! is identified and validated. all DNA
polymorph isms unique to the SW R strain within the mapped Gel! interval will be under
consideration as causative of the trait: however. we have applied a selection scheme for
assessment of potential candidates. with known genes given the highest priority.
Successful reduction of the Gel! interval during the second round of phenotypic
mapping eliminate d a number of genes previous ly considered as candidates for shared
identity with Gctl . including N!I!11Iand 5. IO-melhy! enelelrahydrojil!ale reductase
t Mthf r) . Further refinement of the distal end of Gel ! has beenim pededbya high degree
of repetitive DNA sequence. which has prevented the dcvclopmcn t ofac curatc and
speci fic gcnotyping markers. Should this hurdle be overcome. a more exact boundary
gcnotyping information ofsubcongcnic lines alrcady phcnotypcd. and may reduce the
1.5\ Mbintervalfurther.
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4.2 Priori tiz ing Cel l Candidates: Qu al itative Express io n A na lys is
In an attempt to prioritize candidate genes within the 1.51 Mb Gel / interval for
further investigation . a qualitative assessment ofthc dctcrm inants within the pubertal
SW R and CAST ovary was conducted to achieve two goals : I) to confirm expression in
the mouse ovary at the pubertal stage and. 2) to invcsiigatc diffcrcntiul gene expression
between the tumour-sensit ive and tumour-resistant strains with the hypothesis that the
Gel/ candidate gene may have a severe regulatory mutation that eliminated transcript
productionor increased transcriptturIlo ver. Though notexcludcd th lll1potential Gel /
candidacy. processed transcripts and non-coding RNA genes were not included in this
initial screen. as they were prioritized below protein coding transcripts contained within
the interval. The repelitive natureofthe distale ndofGel /also preventedtheassessment
of three protein coding genes due to lack ofprimer specificity. Further pursuit of these
three genes awaits refinement of the distal interv al boundary by gcnotyping. to firmly
determ ine if they are mapped in or out of the Gel / locus. A fourth protein coding gene
was not assessed as it is interrupted by the proximal marker delineating Gct I. All II
protein coding determinants assessed (CiIl/436 . GII/ / 3 / 78. G1I/438. Dhrs', Vps/3d.
Vps /3 d. Tnfrsfl b, TII!i ·s!S. GII/ /3 225. GII/ /3 242. and GII/ / 32 /2 ) showed positive
expression in ovary cDNA from both strains. and thus no gene candidates were excluded
by this strategy.
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-l.3ThcGct l lntcr":Jl in ~ I () nsc:lll d HUIII:Jn
Cel l is orthol ogous to human Chr Ip36.22. a region that has been implicated in a
number ofd isorders through genome wide association and cytogenetic studics( Figurc
4.1). Kreisel et al . (20 11) identified copy numbcr altc rations at Chr Ip36. 22 ina subset
of diffuse large Bvccll Iymphoma s. an agg ress ive fonn of non-l lodgkins lymphom a.
Human ChI' Ip36 .22 has also been identified as a region frequently lost in human
hcpatoccllu larcarcinoma( Nishimura 1'101. 2006). and is a susceptibility locus for
hcputoccllularcurcinoma in patic ntswit hhcpatit is 13virus infcctio n( Zhang elal. 2010.
Cas pcr elal. 20 1I). Deletions at human Chr Ip36. 22 arc also frequent in infiltratin g
ductal carcinomaof thcbrcast ( l lawthorn elal. 2010). aswcll asprc-mcn opausal brea st
cancers (Varma 1'101. 2005). Loss of heterozygosity at thc Chr Ip36.2 region has been
speculated to be invo lved in ncurobl astoma (Mora 1'101. 2000). and multiple putative
tumo urs upprcsso rgcncs within thc rcgion. buto utsidcCcl l, havc bccn idcnti ficd tGcli
1'101.20 IO. Munir ajan 1'101. 200R. Schlisio 1'101. 200R. Liu 1'101.2 0 I I. Krona et 01.2004.
Chcnelal.2 003) . In addition to thc ussociation between Chr Ip36.22 and neop last ic
conditions. deleti on or dupl ication ofthe region has also been found in cases of
congenital abnormalities includ ing dysmorphic facial features and cardiomyopathy. and
achalas ia (esophageal deformit y). respectiv ely (Kcpplcr-Norcuil 1'101. 1995. Chen 1'101.
20( 6). The identifica tion of Ce l l will permit a cross examination ofthe rolc this Gt,'
tumour susccptibilit y gcnc mightpl ayinothcrdiscasccondit ionsassociatcd with Chr
Ip36.22 in the future .
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Only four well-annotated genes within the Get I interval are conser ved between
mouse and human based on our current knowled ge: DIII's3 , VIIs I 3D , Tllli'sf/h, and
Tllli'slS (Figure 4.1). Given our hypothe sis that mouse GC tumour susceptibility
candidates will provide translational information for juv cni lc-o nsct GC tumour s in young
patient s, these genes have been given top prior ity for further investigat ion. A comparison
off u lly differenti ated tissue-specific expression pattern s is ava ilable for these four
candidates based on the Gene Expression Atlas initiative(Su ct al . 2(04) aeeessed
through the l3ioGPS web portal (Wu ct al . 2009; www .bio gp s.gnf .org) . Relative gene
expression levels determined by microarru y analysis formouse vcrsus hurnan. und fcmalc
versus male gonad.a rc listed inTable4.1. We have included the male gonad informat ion
based ontheevideneethatl11 alemieeofthe GCtul11our susceptiblcSWR strain do not
develop SCST tumours at any age, and we speculate that the Gct l candidate gene either
has ovary-specific funetion s and/orovary-restrietedexpression pattern s. In summary, the
four genes show evidence forexpre ssion in both mouse and human ovary (in agreement
with our qualiuuivc asscssmcnu.with expression ratios that arc comp arablc in thc human
ova ry and testis. but 2 genes show greater expression in the mouse ovary relative to the
testis:DII I's3 (23.85 fold) and Tllli'Sj/h(8.59tllld) . Since it is our goal to identify the
meehanism of GC tumouri gcncsis in the mouse, these genes were of significant interest,
given their reported biological functi ons, and this suggestive expression pattern .
Vps/3 d
Vps l3 d isa iargeande omplex l11 ousegene with muitipie isoflJrlns that has not
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Tu ble -t. I Relat ive ge ne expression in human a nd mou se gua nds, Expression levels
were determined by microarruy (Sue £'1 al . 2(04) an d were acces sed through the BioG PS
web portal (Wu ('/al. 2( 09). IJ!Jrs3and Tnfrsfl h arc highly expressed in the mouse
ovary comp ared to testi s. whereas express ion of a ll four genes is relatively equ al between
human gona ds ,
Relat ive Expression
Ge ne Species Ova ry Tes tis
(ovary /testis)
Mou se 969 .90 4(l.()7 23.X5
IJ!Jrs3
Ilu man 34 .0 4XAO 0.70
Mouse 5.97 4.60 1.29
I'ps l 3d
I luman 9.65 19.65 0.49
Mou se 112.62 13.11 X.59
TII/i"Sjl h
Il uman 7.55 6.75 1.12
Mo use 4 .36 4A9 0.97
TII/i 's/S
I lum an 2.60 4 .0 0.65
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been assig ned a func tion. In hum ans. the VPSI3 D gene en co des a pro tein bel on g ing 10
the vac uo la r-prote in-so rting 13 (V PS I3)gcnc fami ly . In yeas tthese prote ins a rc
involved in the traffi ck ing ofmembrane pro te ins betw een the tran s-G olgi netw ork and
the pre-vacuo larcomp artmen t. Vclayos - Bacza et al. (2004) dcscribcd the four genes in
the human VI'S 13 gene fam ily (V /'S I3;/ throug h D) . Mu tatio ns in the V/,SI3;/ gene
have been assoc ia ted wit h ch orco-acanthocytosis (O M IM 20( 150 ). a ra re , progre ss ive
ncu rod cgcn crat ivcd isord crlhatprcscnls bclwccn lhc lh ird and fif ih dccadcs ofl ifc
( Rampo ldi et al . 200 1. Ucno el al . 20( 1). VPSI 38 has been found to be mu tated in
puiicnts w ith Cohen sy ndrome (O M IM 2 16550). a rurc, non-prog ress ive psychom otor
rctarda lion d iso rdcr charac tc rizcd by mic roc cpha ly. rc lina l dySlrophy . and distincti ve
fac ial fcat urcs( Ko lchmai ncn et al. 2003) . Vc layo s- Bacza e/ al . (2004) dclc rm incd
throug h in silico ana lyses that the VPSI 3 D pro tein may have two put a tive dom ains: a
ubi quitin-asso c iated dom ain (U BA) . which may be invol ved in co nfe rring prote in target
speci ficity in the ub iqu itinat ion pathw ay (Hof ma nn and Buch er 199 6 ). and a ricin -B-
lectin dom ain. whic h is pre sent in many ca rbo hy drate- recog ni tio n prote ins and can bind
sim ple sugars (1lazcs 1996) . Despite a lack of a fun ct iona l ana lysis of VPS I3 D.
Vclayos- Bacza et al. (2004 ) hyp othes ized tha t itthese put ati ve domains arc inde ed
pre sen t, VI'SI 3 D maybc invo lved inlhclraffickingof ubi quitin-t aggc d pro lcin s an d/o r
ca rbohydra tes . T he po tent ial onto logy of Vps13d docs not imme dia te ly highl ight it as the
mo st likel y ca nd idate for Gct l , altho ugh it canno t bc rulcd oulunlilmorc isknow n o f its
function.
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TII/;'s/8
TII/i'sF? is a member of the TNF-receptor superfamily expressed mainly in
activated cells of the immune system (Berro 1.'101.2 ( 04). Downstream signaling from
TII/;'s/8 is mainly transduced through the mitogen-activated protein kinase (MA I'K) and
nuclear fac tor kappa 13(NF-Kl3)pathways (Duckett 1.'101. 1997. Ilorie ct 01. 199X).
TII/i 's/8 signaling can have prolife rative and survival or anti-proliferative and apoptotic
effects depending on the cellular and stimulatory context (Mir 1.'101. 2000. Gruss ct 01.
1994). Serum TII/i'Sj8Ievcls have been found to be increased in patients with
autoimmune diseases and those infected with hepatitis 13. hepatitis C. Epstein-Barr. and
IllY (reviewed by Otlazoglu 1.'101. 2( 09). Furthermore. 711/i's/8 expression is up-
regulated in hematological malignaucics. including l lodgkins and non-l lodgkins
lymphomas (Kaudcwitz 1.'101. 19X6. Granados and l lwang 2004. Stein 1.'101.2 ( 00). The
role ofTII/;·.~/8 in cell proliferat ion. survival. and apoptosis, as well as its increased
expression in blood cancers. enhances its standing as an interesting candidate for Gct l .
Although the action of Gel I is confined to the ovary. the exact cellular compartment has
not been dctcrm ined. und it ispossiblc that am olecularf llctor circulating inlh eblood or
lymph of the ovary may influence growing follicles and disrupt their normal progression.
resulting in malignancy. Thc limited expression pattern of TII/;'s/8 on cells of the
immune system therefore cannot exclude it from thc list ofge ne candidates.
Dhrs3
9X
The human DIIR S3 gene encodes a short-chain dehydrogenase/reductase (SDR).
Other members of the SDR family cata lyze the oxidation/reductio n of steroid hormones.
and include 1 71~ - I I S[) . which cata lyzes the reversible conversio n of androstenedione to T
and estrone to 1:1 (Figure I.X). D/lR S3 is induced by RA (Ccrig noli et al . 2002). and
reduces all-lrallS-relinoI. a storage form of vitamin A. in a process necessary for
photorcccpt ion Il lacsclccrev o/ . 199X). DIIRS3 expression has been found to be up-
regulated in pap illary thyroid carcino mas. although it is negatively corre lated with
subscquenl lymph node mclastasis (Olere l a l.2 00X). Finally. Dhrs3was found to be a
downstream target ofbone morphogenic protein 2 (BMI'2). a TGFI~ fam ily member
expressed in GCs of antral follicles that up-regulates FSII rcccptorand arorna tasc
expressio n. and which maybe involved in lheprcvention of premalur e !(lll icle
luteinizati on (l3iiehncrelaI. 199X.Shi et al. 20 1I). Furlhermorc. BMP2 express ion has
been associa ted with poor prognosis in ep ithelia l ovaria n cancer (Lc Page et al. 2009 . Ma
('/ al . 2010) . The knowledge that D/lRS3 belongs to an enzy matic family that catalyzes
steroid horm one conversion . that it is induced by RA. the initia torofoocyt e meiosis. and
that it has been associate d with epithelial ovaria n cance rprogressio n. elevates the mouse
DhrsI gene in the prioritized ranking of GCII candidate genes.
Tnfsrsf l h
Tnfrsf l b. a mcmber of lhc TNF-receplor superflllnily. isa type l transmcmbranc
recepto r that binds tumour necrosis factor alpha (TNFa) . Thc Tnfrsfl b protein cons ists
ofa cysleine-richexl raeellular domain lhal issi milar lo lheex tracellular domain of
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Tnfrsf'la, the other receptor fix TNFa . Binding ofthc receptors to their ligand shows a
3/3 stoichiometry, in which a complex of three TNFa molecules bind three receptors
( Banncrel a l. 1993). The subsequent conformational change in the receptors'
cytoplasmic tails results in signal transduction (Chan et al. 2( 00). TnIrsfI a and Tnfrsf'lb
dit1erinthei r cytoplasmicdomains, which rclatcstothcirdifteren tmodcsof action .
Tnfrsfl b contains a short, C-tcrminal intracellular region that is involved in binding TNF
receptor associated factor 2 (TRi\ F2). TRi\F2 binding triggers the recruitment of
cellular inhibitor of apoptosis I (c-li\ PI) andc -li\ P2, which Icadst oJun N-tcnn inal
kinase (JNK) and NF-KB activation, result ing in cell survival and proliferation. On thc
other hand, Tnfrsf'la activatcs thc caspasc cascade, result ing in cell death through
apoptosis trcvicwc d by Carpcntier el al. 2( 04).
TNFa potcntially rcgulatesa number ofprocess es in the mammalian ovary,
including that of germ cell cyst breakdown and follicle formation. oocyte death,
gonadotropin-induccds teroidogenesis,and GC proliferation orapoptosis dcpending on
thcf i.1 I1icularcontcxt( Morrison andM arcinkiewicz2 002,So n eta l 2004, Terranova
1997, Kai pia elal. 1996, Sasson el al. 2002, i\bd o el al . 2(0 3). When signaling through
Tnfrsf'l b. TNFa may also regulate initial follicle recruitment, as TII! i's!J b null mice had
increased growing follicle cohorts compared to controls (Grccnte ld elal. 2( 07) . In
humans, the p.M 196R TNFRSF IB variant has been associated with hypcrandrogcnism
and polycystic ovary syndrome in women (Pcral et al, 2( 02). An established role for
TII!i·.I/ Jh in the ovary and its activation of pathways resulting in prolife ration and cell
survival strengthens its standing as the best potential candidate for Gct l .
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4.4 Summary
The SWR mou se model for GC tumourigcnc sis is a un iqu e and realis tic modcl for
genetica lly compl ex and stochas tic cancer risk in genera l. and more specifica lly. a
reco gni zed model for juvenile GC tum our s in ped iatri c patien ts . Pursuit of GC tum our
suscc ptib ilitygcncs in thc mou sc will provide s pecific cand idate s f o r fu rt h er inv es tiga tion
in j uve ni le GC tumo ur cases, to e lucidate a genetic etio logy for this unique ovarian
tumour class . A ph enotyp e-d riven ma ppin g stra tegy usi ng congcnic lines to iso late thc
funda mc nta lGel l loc us hassucccssti illy rcso lvcd thc gc nct ici ntcrva l to 1.51 Mb . us ing
DI IEA sti mulatio n at pube rty to increase tra it pcnctrancc fix thc purpose o f mapp ing.
T he refi ned interval in thc mou sc is still re lati ve ly gene-ric h, wi th 43 en titie s curre nt ly
annota ted, a lthoug h 20 arc rep etitive psc udo gc ncs that havc hind ered reso lutio n ofthc
d istal inte rva l boundary. 0 1'23 total genes , II prot ein -cod ing genes underwent
qu a litativcgcneexprcssion asscssmcn t in thc puberta l mou sc ovary. and showed posi tive
evi dence for expression that was s imi lar between GC tumour-su sce ptible and resist ant
tCmalcs .csscntia llyclimi na ting non e from the searc h for Gct l . Our prior itization
strategy fo r thc rem aining gene can didate s foc use d on the known gcncs that wer e also
pre sent in thc homo logou s human inter val on ChI' Ip36 .22: DhrsI, Vps l Id, TII/i's/S,
Tnf rsl b, Func tiona l in format ion for TII/i·.I'/lh made it a ve ry interes ting and probable
ca nd idate fo r Gct l . Seque ncing of the cod ing reg ion d id no t rev ea l va riat ions that were
un iqu e to thc SWR st ra in. a ltho ug h two dinuc leo tide del eti ons in thc 3' UT R region s of
thc S W R tra nscri pt co uld potent iall y impact tran scr ipt stability . DI IEA trcaun cut of
tumo ur suscep tibleorrcsistan tovaric sd id no t ai tc rTllji4 1h gcn ecx prcssio n. and so did
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not shed light on DIIEA responsiveness, or Tnfrsflb candidacy. The low phenotypic
pcnctrancc ofG C tumours in the SWR mouse model, and the lack of an overt phenotype
in male SWR mice, suggests a subtle mutation unique to this strain may interfere with a
normal ovarian process. leading to tumourigcncsis in only a small fraction of mice.
Strategies to resolve Get I identity will incorporate additional genotype refinement, but
also fine-phenotype analysis. forcon siderat ion of which ovarian cellular compartment
Get! may act through or influence to initiate GC tumour fo rmation. Close examination
of pre-neoplasti c follicular lesions by immunohistochem istry for the protein-coding
candidate genes identified will complement the strategies already cmploycd li)r Get!
identification .
4.5 Future Directions
I) To improve mapping resolution and exclude potential gene candidates, relini ng
the Get ! interval using the six phcnotypccl. congcnic sublincs is the greatest
priority
2) Sequencing of the coding and regulatory regions oflJ/irs3 and a quantitative
expression analysis similar to that performed for Tnf rsflb, to determ ine if the
SWRIJ/irs3cDNA possesses a unique variant or is differentially expressed in the
SWRovary
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3) Proleinexpre ssion pall ern sinearl ypre-neoplasli cf'llllicie sby
im muno histoc hem istry, to reveal informa tion abo ut ce ll-specific pro tc in
expression forthe four known prot e in co d ing genes hom ologou s between mou se
and human. in the pre sen ce or abse nce ofD l lEA
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Ap pe ud ix A
Contributions
• Sara h l la lfya rd. u rcscarch assis tant in the Dorward labor ator y. identi fied . desi gn ed .
and tested nov el SS LP geno typing mark ers (D asjhIU, Dqsjhl l , D4sjhl 2 . D4sjhl 3
and D4sjhI9) . and co nduc ted sequenc ing of Np pb, for the purpo ses of phenot yp ic
mappin g at Gct l . Ms. Ii a lfya rd conducted the majorit y of subline ge nera tion (n = 6)
andgenoty ping until December 2009. whe n the proj ect transitioned into my hand s.
Overall. I was resp on sibl e fo r the majorit y ofthe ca psule imp lant ation surgerie s and
phenot yp e ana lys is. fine mapping of the GetI inter val. and candidate gene testin g.
• Katie Macd onald. an MSe stude nt in the Dorward labo ratory. colle cted se rum
sa mples from S W R and Line 4-1' mice fix the serum DI IEA ana lysis .
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Appendix C
Harvard Primcrl3ank IDs for primer sequences used in the qualitative gene
express ion analys is
Harvard
Gene
PrimcrBank ID
GIII436 147905R92b2
GIII /3 / 78 14R222100b3
Dhrsi 14290432a3
Vps / 3d IR9491RRRb2
Tnli -,If l ll 6755R27a2
Tnli -slS 667R3R5a2
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Appendix D
Alignment of the SWR, Line 4-T (4-T), and 86 Tnfrsflb cDNA nucleotide
sequences. Bp differences in SWR comparedto Line4-T and 86 are highlighted.
* : identities: -: deletion: gaps: nucleotide changes.
4 - T AGT CA C CA GC TA GAGCGCA GCT GAGGCA CT AGAGCT CCA GGCA CAA GGGC GGGAGCCACC
S WR AGT CA C CAGC TAGAGC GC AGC T GAGGC AC TAGAGC T CCA GGCACAA GGGCGGGAGC CAC C
B6 AGT CA CCA GCTA GAGC GCA GCT GAGGCA CTA GAGCT CCA GGCA CAA GGGC GGGAGC CA CC
4 - T GC TGCCCCTATGGCGCCCGCCGCCCTCTGGGTCGCGCTGGTC TTCGAACTG CAG CT GT GG
S WR GC TGCCCC TATGGCGCCCGCCGCCCTCTGGGTCGCGCTGGTCTTCGAACT GCAGC T GT GG
B 6 GC TGCC CCTA TG GC GC CC GC CGCC CT CT GGGT CGCGCT GGTC TTC GAAC TGC AG CT GT GG
4 - T GCC ACCGGGCAC AC AG TGCC CGCCCAGG T TG TC T TG AC ACC CT AC AAA CC GGAA CCT GGG
S WR GCC ACCGGGC AC AC AG TGCCCGCCC AGG T TG T CT TG AC ACCC TAC AAAC C GGAA CCT GGG
B 6 GC CACC GGGC AC AC AG T GCCCGCC CAGG TT GT CT TGACA C CC TACAAAC CGG AA CC TG GG
4 - T TACG AG TGCC AGATC TC AC AGG AA TAC TATG AC AGG AAG GCTC AGAT GT GCT GT GC TAAG
S WR TACG AG TGCC AGATC TC AC AGG AA TA CT AT GACAG GAA GGCT CA GAT GT GCT GT GC TAA G
B 6 TACG AG TGCC AGATC TC ACAGG AA TA CT AT GACA GGAA GGCT CA GAT GT GCTGTGC TAA G
4 - T TGT CC TCC TGGCCAATATGTGAAACATT T CT GCAA CAA GACC TCGG AC ACCG TGT GT GCG
S WR TG TCC TCC TGGC CAAT AT GTGAAA CA TT TCTGCAAC AAG ACCTCGGACAC CGTGTG TGC G
B 6 TG TCC TCC TGGCCAAT AT GT GAAA CA T TTC TGCAA CAA GACC T CGGACA C CGT GT GTGCG
4 - T GAC TG TG AGGC AAGC AT GTA TA CC CA GGT CT GGAA CCA GT T T CGTA CA TGTTTGAGCTG C
S WR GAC TG TG AGGC AAGC ATG TATA CC CA GGT C T GGAA C CA GTT T CGTA CA TGTT TG AGCT GC
B 6 GAC TG TG AG GC AAGC AT GTA TA CC CA GGT CT GGAA C CA GTT T CGTA CA TG T TT GAGCT GC
4 - T AGTT CT TC CT GT AGCA CT GACCAG GT GGAGACC CGCGCC T GCA C TAAA CAGCAGAA CC GA
S WR AGTTCT TC CT GTA GCACT GACCA GGT GGAGAC CCG C GC C T GCA CTAAACA GCA GAA CC GA
B 6 AGTT CTTC CT GT AC CACTGACCA GGT GGAGATCC GC GC CT GCA C TAAA CA GCA GAA CC GA
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4 - T GTG TG TGC T T GCGAAGC TGGC AGG TAC TGCGCC TTG AA AACCC A T TCTGGCAGCTG TCG A
SWR GTG TG TGC T TGCG AAGC TGGC AGG TACTGCGCC T TGAA AACCC A T TC TGGC AGC TGTCG A
86 GTG TG TGC TTG CGAA GCT GGCA GGTA CT GCGCCTTGAAAACCCA TT CT GGCA GCT GT CGA
4 - T CAGTGC ATG AGGC T GA GCAAG TGCGGCCC TGGC T TCGG AG TGGCC AG T TC AAG AGCCCCA
SWR CAG TGC A TG AGGC TGAG CAAG TGCGGC CCTGGC T TCGG AG TGGCC AG TTC AAG AGCCCC A
86 CAG T GCA TGAG GCT GAGCAA GT GCGGCCCTGGC T TCGGAG TGGC CAG T TCAA GAGCCCCA
4 - T AA T GGAAA T GT GCTATGCA GGGCCT GT GCCCCA GGGACA TT CTCT GACA CCA CA TCA T CC
SWR AA TGGAAA T GT GCTATGCAA GGCCTGT GCCCCA GGGACGTT CT CT GACACCA CA TC ATCC
86 AA TGGAAA TG TGC TAT GCAA GGCCT GT GCCCCA GGGACGT T CT CT GACA CCA CA TCA TCC
4 - T ACA GAT GT GT GCA GGCCCCA CCGCA T CT GT AGCA TCCTGGC TAT TCCCGG AA ATGC AAGC
SWR ACA GAT GT GTGCAGGCCCCA CCGCAT CT GTA GCA TCCT GGCT ATT CCCGGAAAT GCA A GC
86 A CT GAT GT GTGCA GGCCCCA CCGCAT CT GTA GCA TCCT GGCT ATTCCCGGAAA TGCAAGC
4 - T ACA GAT GCA GT CT GTGCGCCCGAGT CCCCAA CT CTAAGTGCCA T CCCAA GGACA CT CT AC
SWR ACA GAT GCA GTCT GT GCGCCCGAGT CCCCAA CT CTAA GT GCCAT CCCAA GGACA CT CTAC
86 A CA GAT GCA GTCTGT GCGCCCGAGT CCCCAA CTCTAA GT GCCA T CCCAA GGACA CT CTA C
4 - T GTAT CT CA GCCA GAGCCCA CAA GA TCCCAA CCCCT GGA TCAA GAGCCA GGGCCCA GCCAA
SWR GT AT CT CA GCCAGAGCCCA CAA GA TCCCAA CCCCTGGAT CAA GAGCCA GGGCCCA GCCAA
86 GTAT CT CAGCCA GAGCCCA CAA GAT CCCAA CCCCT GGAT CAA GAGCCA GGGCCCA GCCAA
4 - T ACT CCAA GCA T CCTTACA T CGTT GGGTT CAA CCCCCATTATT GAA CAAAGTA CCAA GGGT
SWR ACT CCAA GCA TCCTTACA T CGTT GGGTT CAA CCCCCATTATTGAA CAAAGTA CCAA GGGT
86 ACT CCAA GCA TCCTTACAT CGTT GGGTT CAA CCCCCATTATTG AAC AA AGT ACC AAGGGT
4 - T GGCA T CT CT CTT CCAA TT GGT CTGATTGTT GGAGTGACAT CA CTG GGT CT GCTGAT GTTA
SWR GGCA TC TC TC T TCC AA TT GGT CT GATTGTTG GAGTGACAT CACT GGGT CT GCT GA T GT TA
86 GGCA T CT CTCT T CCAA TT GGTCTGAT T GTT GGAGT GACAT CACT GGGT CT GCT GAT GTTA
4 - T GGAC TGG TGAAC TGC T TC A TCC TGG TGC AGAGGAAA AAG AAGCCCTCCTGCCTACA AAGA
SWR GGAC TGG TG AACT GCT TC ATCC TGG TGC AGAGGAAA AAG AAGCCC TCC TGCCT AC AAAG A
86 GGAC TGG TG AAC TGCA TC ATCC TGG TGC AGAGGAAA AAG AAGCCC TCCTGCC TAC AAAGA
4 - T GA TGCCAA GGT GCCT CAT GT GCCT GATGAGAA AT CCCAGGAT GCA GTA GGCCT T GAGCA G
SWR GA T GCCAA GGT GCCT CAT GT GCCT GATGAGAAATCCCA GGAT GCA GTA GGCCT T GA GCA G
86 GA T GCCAA GGT GCCT CAT GT GCCT GA TGAGAAATCCCA GGAT GCA GTA GGCCTTGAGCA G
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4 - T CAGC ACC TG T TG AC CACAGCACCC AGT TCC AGC AGC AGC TCCC TAGAGAGCTCAGCCAGC
S WR CAGC ACC T GT TG AC TAC AGC ACCC AG TTCC AGC AGC AGC TCCC TAGAGAGC TC AGCCAGC
B 6 CAGC AC C TG TT GAC CACAGCAC CC AG T T CC AGC AGC AGC TCC C TAGAGAGCTC AGC CAGC
4 - T GC TG GGG ACCG AAG GGC GCCCCCTGGGGGCCA TC CC CAA GCAA GAGTCAT GGCGGAGGCC
S WR GC T GGG GAT CGAAGGGCGCC CCC T GGGGGC CAT C CC CAA GCAA GAGT CAT GGCGGAGGCC
B 6 GCTGGGGA CCG AAGGGCGCCCCC TGGGGGCCAT C CC CAA GCAA GAGTCAT GGCGGAGGCC
4 - T CAAGGG T T TC AGGAG GCC CG TGCC AGC TCC AGG A TTTCA GATT C TT CC CA CGGAA GCCA C
S WR CAAGGG T C TC AG GAG GCCC GC GCC AGC TCC AGG AT TTCAGATTCTTCCCACGG AAGCC AC
B 6 CAAGGG T T TC AGG AGGCCCG TGCC AGC TCC AGG AT T T CA GAT TC TTCCCACGG AAGCC AC
4 - T GGG ACCCl>.CG TC AACG TC ACC TGC ATCGTGAACG TCTGTAGC AGCTCTGACC AC AGCTCT
S WR GGGAC CC ACG TC AACG T CACC TGC ATCG TG AACGTCTGTAGC AGCTCTGACC AC AGCTCT
B6 GGG ACC CACG TCAACG TC ACC TGC ATCGTGAACG TCTG TAGC AGC TC TG ACC AC AGTTCT
4 - T CAG TG C TC T TCCCAAGCC AGCGCC ACGGTGGGAGACCC AGATGCC AAGCCCTCAGCGTCC
S WR CAG TGC TC T T CCC AAGCC AGCGCC ACGGTGGGAGACCC AGATGCC AAGCCC TC AGCGTCC
B 6 CAG T GC T C T T CC CAAGC CAGCGCC AC AG T GGGAGACCC AGAT GC CAAGCC CT CAGC GT CC
4 - T CC AAAGG ATGAG CAG GT C CCCTTCT CT CA GGAGGAGT GT C CGT C TCA GT C CC CGTA TG AG
S WR CC AAAGGATGAGCAGGT C CC CT T CTC TCA GGAGGAGT GT C CGT CT CA GT C CC CGTA TG AG
B 6 CC AAAGG AT GAG CA GGT C CCCTTC TCT CA GGAGGAGT GT C CGT CT CA GT CC C CGT GT GAG
4 - T AC TA CA GAGACA CTG CA GAGCCAT GAGAA GCCCTTGCC CCT T GGT GT GCC GGAT ATGGGC
S WR ACTA CA GAGACA CTG CAGAG CCAT GAGAA GCCCTTGCCCC TT GGT GT GCCAGAT ATGGGC
B 6 ACTACAGAGACACT GCA GAGC CAT GAGAA GCCCTTGCC CCTT GGT GT GCC GGA T ATGGGC
4 - T ATGAAG CC CA GC CAA GCTG GCTG GTTTGAT CA GATT GCA GTCAAA GT GGC CT GACC CC TG
S WR AT GAA GCC CAGC CAA GCT GGCT GGTTTGATCA GATT GCA GT CAAA GT GGC CT GACC CC T G
B 6 AT GAA GCC CA GCCAAGCTGGCTG GTTTGAT CA GATT GCA GT CAAA GT GGC CT GACCC C TG
4 - T ACA GGGGTAA CAC C CTG CAAA GT GAC CCCC GAGACC CT GAA C CCA T GGAA CT T CA T GACT
S WR ACA GGG GTAACACCCTGCAAAG T GACCC CC GAGACCC T GAA CCCAT GGAA CTT CA T GAC T
B 6 ACA GGGGT AACA CC CT GCAAA GGGACCC CC GAGACC CT GAA C CCAT GGAA CT T CA T GAC T
4 - T TTTGCT GGAT CCATTT CC CTTAGTGGCTTC CA GAGC CC CA GTT GCA GGT CAA GT GAGGGC
S WR TTTGCTGGATCCATTTC CCTTAGT GGCTTC CA GAGC CC CA GTT GCA GGT CAA GT GAGGGC
B6 TTTGCTG GATCCATTTCC CTTAGT GGCTTC CA GAGC CC CA GTT GCA GGT CAAGT GAGGGC
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4 - T TGAGGCAGC TAGAGTGGTC AAA AACTGCCATGGTGT TT TATGGGGGCAGTCCC AGGAAG T
SWR TGAGGCAGCTAGAGTGGTC AAA AAC TGCC ATGGTGTTTTATGGGGGCAGT CCCAGGAA GT
B 6 TGAGACAGC TAGAGTGGTCAAAAACTGCCA TGGTGTTT TATGGGGGCAGTCCCAGGAA GT
4 - T TGTTGC TC TTCC ATGACCCC TCTGG ATCTCCTGGGCTC TTGCC TGATTC TTGCT TCT GAG
SWR TGTT GCT CTT CCAT GACCCCT CT GGATCT CCTGGGCTCTT GCCT GATTC TTGCT TCTG AG
B 6 TGTTGC TC TT CCAT GACCCCT CT GGATCTCCTGGGC TCT T GCCT GATT CT TGCT TCT GAG
4 - T AGGCCCCAGTAT CTTTTCCTT CTAA GGAGCTAA CAT CCT CT TCCAT GAA TA GCACAGCTC
SWR AGGCCCCAGTAT CTTTTCCTT CTAAGGAGCTAA CAT CCTCTT CCATGAAT AGCACAGCTC
B 6 AGGCCCCAGTATTTTTTC CTT CTAA GGAGCTAA CAT CCT CTT CCAT GAA TAGCACAGCTC
4 - T TT CAGCCT GAAT GCT GACACT GCAGGGCGGTT CCAGCAA GTA GGAGCAA GTGGTGGCCTG
SWR TT CAGCCT GAAT GCT GACACT GCAGGGCGGTT CCAGCAA GTA GGAGCAA GTGGTGGCCT G
B6 TT CAGCCT GAAT GCT GACACT GCAGGGCGGTT CCAGCAA GTA GGAGCAA GTGGTGGCCTG
4 - T GTAA GGCACAGAGGCCCTT CAGGT TA GTGCTAAACT CT TA GGAA GTACCCTCTCCAAGCC
SWR GTAAGGC ACAGAGGCCCT TCAGGTTAGTGCT AAAC TC TTAGGAAGT ACCCTCTCCAAGCC
B 6 GTAGGGCACA GAGGCCCTT CAGGTTA GTGCTAAACT CTTAGGAA GTACCCT CT CCAAGCC
4 - T CACCG AAA TT CTTTTGAT GCAA GAAT CAGAGGCCCCAT CAGGCAGGGTTGCTCTGTTA TA
SWR CACCG AAA TT CTTTTGATGCAA GAAT CAGAGGCCCCAT CAGGCAGAGTT GCT CT GT TA TA
B 6 CACCG AAA TT CTTTTGATG CAA GAA TCAGAGGCCCCAT CAGGCAGAGTT GCT CT GT TATA
4 - T GGATGGT AGGGC TGTAA CT CAGTGGTCCAGTGTGCTTT TA GCATGCCCTGGGT T TGATCC
SWR GGAT GGTAGGGCTATAA CT CAGTGGTCCAGTGTGCTTTTAGCAT GCCCTGGGTT TGATCC
B 6 GGATGG TAGGGCTGTAAC TCAGTGGTCC AGTG TGCT TT TAGCAT GCCCTGGGTTTGATCC
4 - T TC AGCAACATAT GCAAAACGTAA GTA GACAGCAGACAGCAGACAGCACAGCCAGCCCCCT
SWR TCAGCAA CACAT GCAAAACGTAA GTA GACAGCAGACAGCAGACAGCACAGCCAGCCCCCT
B6 TCAGCAA CACAT GCAAAACGTAA GTA GACAGCAGACAGCAGACAGCACAGCCAGCCCCCT
4 - T GTGTGGTT TGCAGCC TC TGCC TTTGACT TTT AC TCTGGTGGGC ACACAGAGGGCTGG AGC
SWR GTGTGGTT TGCAGCC TC TGCCT TTGAC T TT TAC TC TGGTGGGC ACACAGAGGGCTGGAGC
B 6 GT GT GGTT TGCAGCCTCTGCCT TT GAC T TT TA CTCTGGTGGGCACACAGAGGGCTGGAGC
4 - T TCC TCC TCCT GACCTT CTAA TGAGCCC TTCC AAGGCCACGCC TTCCTTCAGGGAATCTCA
SWR TCCT CCTCCT GACCTT CTAA TGAGCCCTT CCAA GGCCACGCCTT CCTTCAGGGAA T CT CA
B 6 TCCT CCTCCT GACCTT CT AA TGAGCCCTT CCAA GGCCACGCCTT CCTTCAGGGAA TCTCA
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4 - T GGGACT GTAGAGT TCCC A GGCCCC TGC A GCCA CCTG TC TCT TCC TACC TC AGCC TGGAGC
SWR GGGAC TG TAGAG T TCC CAGGCCCCTGCAGCC ACC TGT CTCTTCCT A CCT CAGCCT GGA GC
B 6 GGGA CT GTAGAGTT CCCA GGCCCCT GCA GCCA CCTGTCTCTT CCTA CCTCA GCCTGGAGC
4 - T ACT CCCT CTAACT CCCCAA CGGCT TGGTA CTGTA CT CGCT GT GACCCCAA GT GCA TGTCC
SWR ACT CCCT CTAACT CCCCAA CGGCTT GGTA CT GTA CT CGCT GT GA T CCCAA GT GCAT GT CC
B 6 ACTC CC TCT AAC TCCCCAA CGGCT T GGT ACT GTA CT TGCT GT GACCCCAA GT GCA T GT CC
4 - T GGGT TA GGCAC T GT GA GT TGGAAC AGCT GA T GACA T CGGT T GAAA GT CCCACCCGGAA A C
SWR GGGT TA GA CACT GT GA GT TGGAAC AGCT GA TG ACATC GGT TGAA AGGCCC ACCCGG AA AC
B 6 GGGT TA GGCA CT GT GA GT T GGAAC AGC TG A T GACAT CGGTT GAA AGGCCCA CCCGGAAA C
4 - T AGCT GAA GCCA GCT CTTT T GCCAAAGGA TT CA TGCCGGT T T T CT AA TC AACC TGC TCCCC
SWR AGCT GAA GCCA GCT CT T T T GCCAAAGGA TT CA T GCC GGTTTTCTAA T CAA CCT GCT CCCC
B 6 AGCT GAA GCCA GCT CTTTTGCCAAAGGAT T CA T GCCGGT TT T CTAA TCAA CCT GCT CCCC
4 - T TAGC A TGCC TGGAAGG AA AGGG T TC AGGAGAC TCC TCA AGAAGC AAGT T CA GT CT CAGGT
SWR TA GCAT GCCT GGAA GGAAA GGGT T CA GGAGACT CCT CAA GAA GCAA GT T CA GT CT CAGGT
B 6 TA GCAT GCCT GGAA GGAA AGGGTT CA GGAGACT CCT CAA GAA GCAA GTT CAGTCTCAGGT
4 - T GCT T GGAT GCCA TGCT CA CCGA T T CCAC TGGA TA TGAAC T TGGC AGAGGAGCC TAGT TG T
SWR GCT TGGA TGCC A T GCTC A CCGATT CCACTGGATA TGAACTTGGCAG AG GA GCCT AGTT GT
B 6 GCT T GGA T GCCA T GCT CA CCGAT T CCA CT GGATA T GAA CT TGGCA GAGGAGCCT AGTT GT
4 - T T GCCAT GGAGACTTAA AGAGCT CA GCA CT CTGGAA T CAAGAT ACT GGA CA CTT GGGGCCG
SWR TGCC AT GGAGAC TT AAA GAGCT CA GCA CTCTGGAA T CAA GATA CT GGACA CT T GGGGCCG
B 6 T GCCAT GGAGACTTAAAGAGCT CAGCA CT CT GGAA T CAA GATA CTGGACA CT T GGGGCCG
4 - T ACTTGT TAA GGCTCTG CA GCAT CA GACT GT AGAGGGGAA GGAA CA CGT CT GCCCCCTGG T
SWR ACT TGT TAAGGC TCTGCAGC ATC AGAC TG TAGAGGG GAAGGAAC AC GTCT GCCCCCT GGT
B6 ACTT GT TAAG GCT CT GCA GCA T CA GACT GTA GAGGGGAA GGAA CA CGT CT GCCCCCT GGT
4 - T GGCCAGTCC T GGAA TGA CCT CGGGCCT CCTA GGCAA CAAAAGAA TGAA TT GGAA AGGACT
SWR GGCCAGT CCT GGGA TGA CCT CGGGCCT CCT AGGCAA CAAAAGAA TGAA TT GGAA AGGACT
B 6 GGCCCGT CCT GGGA TGACCT CGGGCCT CCT AG GCAAC AAA AGAA T GAATTGGAAAGGACT
4 - T GT T CCT GGGT GT GGCCT CA GCT CCT GT GCT TGT GTG GA T CCCTAAAGGGT GT GCTAAGGA
SWR GT TCCT GGGT GT GGCCT CA GCT CCT GTGCT TGT GTGGA TCC T GAAA GGGTG TGC TAAGGA
B 6 GT TC CT GGGT GT GGCCT CA GCTC CTGT GCTT GT GT GGA TCCCTAAA GGGT GT GCTAA GGA
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4 - T GCAA TTGC ACTGTGTGCTGGACAGAA TTCCTGCTTAT AAA TGC TT TT TGTTGTTGTTTTG
SWR GCAA TTGC AC TGTGTGCT GGACAGAA TTCCTGCTT A TAAA TGCT TTTTGTTGTTGTTTTG
B 6 GCAA TTGCACT GTGTGCT GGACAGAA TTCC TGCT TA TAAA TGC TT T TTGTTGTTGTTTTG
4 - T TACAC TGAGCCCTGGCTG TGTCTAGGTCTGG AGCCACCCC ACCCCACC TCCC ATCCCACC
SWR TACACTGAGCCCT GGCT GTGTCTA GGTCTGGAGCCACCCCACCCCACCTCCCA TCCCACC
B6 TAC ACTG AGCCCTGGCTG - - - - - - - - - - - - - AGCCACCCC ACCCC ACCTCCCATCCCACC
4 - T TTTACAGCC ACTCTTGCAGAGAACCTGGCTATCTCCCACTTGTAGCCTGTGGATGCTGAG
SWR TTT ACAGCC AC TCT TGCAGAGAACCTGGC TATCTCCCACTTGTAGCCTGTGGATGCTGAG
B6 TT TACAGCC AC TC TTGC AGAGAACC TGGCTGTC TCCC ACTTGTAGCCTGTGGATGCTGAG
4 - T GAAGCACCC AGCCAAGT AGACTCC AGGCTTGCCCCTATCTCCTGCTCTGAGTCTGGCC TC
SWR GAAGCACCC AGCCAAGTAGACTCC AGGCTTGCCCCT ATCTCCTGCTCTGAGTCTGGCCTC
B6 GAAAC ACCC AGCC AAGTAGACTCC AGGCTTGCCCCTATCTCCTGCTCTGAGTCTGGCCTC
4 - T CTC A TT GT GTT GTGGGAA GGAGACGGGT TCT GTCATCTCGGAA GCCCACACCGTGGATGT
SWR CTC ATTG TGT TGTGGGAAGG AGACGGGT TC TGTCATC TCGGAAGCC TACAC TGTGGATGT
B 6 CTC ATTGTGT TGTGGGAAGG AGACGGGTTC TGTCATCTCGG AAGCC CACAC CGTGGATGT
4 - T GAACAA TGGCT GTA CT AGCT TA GACCAGCTTA GGGCTCTGCAAT CAGAGGAGGGGG- GCA
SWR AA CAAT GGCT GTACTA GCTT AGACCAGCT TAGGGCT CT GCAA TC AGAGGAGGGGG- GCA
B 6 AA CAAT GGCT GTA CTA GCTT AGACCAGCTT AGGGCT CT GCAA TCAGAGGAGGGGGAGCA
4 - T GGAAC AATTTGAGTGC TGACCT ATAA CACATT CCTAAAGGATGGGCAGTCCAGAA TCTC
SWR GGAAC AAT TTGAGTGCTGACCT AT AA CACATTCC TAAAGGATGGGCAGTCCAGAA TCTC
B6 GGAAC AAT TTGAGTGC TGACCT AT AAC ACATTCC TAAAGG ATGGGCAGTCCAGAATCTC
4 - T CTCC TTC AGTGTGT GTGTGTGTGTG TGTGTG TGTGTGTG TGTGTGTGTGT GTGTGTGTG
SWR CTCC T TCAGTGTGTGT GTGTGTG TGTGTG TGTGTGTGTG TGTGTGTG TGT - -GTGTGTG
B 6 CTCCTT CAGTGTGTGTGTGTGTGTGTGTGTG TGTGTGT GTGTGT GTGTGTCCAT GTTT G
4 - T TGTGTGTGTGTGTGCCAGTGTGTGGAGGCCAGAGGT TGGCTTTGGGTGTGTTTGATCACT
SWR - - TGTGTGTG TGTGC CAGTGTGTGG AGGCC AGAGGTTGGC TTT GGGTGTGTTT GATCACT
B 6 CA TGTA TGTGTGTGCCAGTGTGTGGAGGCCAGAGGTTGGCTTTGGGTGTGTTTGATCACT
4 - T CTC AGTGT AC TGAGGCAGGGCTCTCATCTGCACCC AGAGCT TGCACATTTTCTAGTCTAA
SWR CTC AGTG TACT GAGGCAGGGCT CT CA TCTGCACCCAGAGCTTGCACATTTTC TAGTCTAA
B 6 CTC AGT - TACTGAGGCAGGGCTCTCA TCTGTA CCCAGAGCT TGCACA TTTTC TAGTCTAA
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4 - T CT TGCTTCAGGGATCTCTGTCTGCCTAT GGAGTGCT CAGGTTACAGGCAGGCT GCCATAC
SWR CTTGCTTCAGGGAT CT CT GTCT GCCTAT GGAGTGCTCA GGTTACAGGCAGGCTGCCATAC
B 6 CT TGCT TCAGGGAT CT CT GTC TGCCTATGGAGTGCTCAGGTT ACAGGCAGGCTGCCATAC
4 - T CTGC CCAAC A TT TACA TGAA TACT AGAGATC TGAATT CT GGTCCT CACACT TGTAAACCT
SWR CTGCCCAA CA TT TACA TGAA TACTAGAGAT CT GAAT TCTGGTC CTCACAC TTGTATACCT
B 6 CTGCCCGACA TTTA CATGAA TA CTA GAGAT CT GAA T TCT GGTCCTCACACTT GTATACCT
4 - T GCAT TTT ATCC ACTAA GACAT CTCTCCAA GGGCT CCCCCT TCCTA T TTAA TAA GT TA GTT
SWR GCAT TTT A TCC AC TAA GACA TC TCTCC AAGGGCTCCCCC T TCC TATTTAAT AAGTT AGT T
B 6 GCAT TT TA TCCACT AA GACA TCT CTCCAAGGGCT CCCCCT TCCT AT TTAA TAA GTTA GTT
4 - T TT GAACTGGC AA GATGGCT CAGTGGGTAA GGCAGTT TGCGGACAAA CCTGAT GACCTGAG
SWR TT GAAC TGGCAAG ATGGC TC AGTGGGTAAGGCAGTTTGCGGA CAAA CCTGAT GACCTGAG
B 6 TTG AAC TGGCAAG ATGGC TC AGTGGGTAAGGCAGTTTGCGGACAAA CCT GAT GACCT GAG
4 - T TT GGAT CCCTGACC ATAA GGTA GAAGAGACCT GATT CCTGCAAGTT GT CCTCT GACCACC
SWR TTGGATCCCTGACC ATAAGG TAGAAGAGACCTGAT TCCT GCAAGTT GTCCT CT GACCACC
B 6 TT GGATCCC TGACC ATAA GGTA GAA GAGACCT GATT CCTGCAA GTT GT CCTCTGACCACC
4 - T ACCC CATACATGC T TCTGCATATGTGC ACACATC ACATTCT TGTA CAGACACT CACA TA C
SWR ACCCC ATA CATGCTTCTGCATATGT GCACACATC ACATTCTTGTACAGACACTCACA TAC
B 6 ACCCCA TA CA TGC T TC TGCA TA TGTGCACACAT CACATTCT T GCACACACACTCACATAC
4 -T CA TAAA TGTAATAA AT TT TTTAAA AA TAAA TTGA TT TTAT TT TT TAATC ATT A
SWR CATAAA TGTAATAA AT TT TT TAAA AA TAAA TTGATT TTATT T TTTAATCA TTA
B 6 CATAAA TGTAATAA AT TT TT TTAA A - TAAA T TGATT TTAT CTT TTAATCAT TA
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